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  SUMMARY 
 
Background: Primary cardiac tumors represent a rare entity in cardiac surgery but have the 
potential to cause significant morbidity if not treated in an appropriate and timely manner. The aim 
of the study was to investigate the incidence, histopathology and survival characteristics of patients 
who underwent surgical resection in Veneto Region in the time interval 2005-2016.  
 
Material and Methods:  
A Regional Registry of primary cardiac tumors was created from data of 6 Cardiac Surgery 
Institutions of Veneto Region (Mestre, Treviso, Mirano, Padova, Vicenza and Verona), gathering 
retrospectively all consecutive patients who underwent surgical resection in time interval 2005-
2016 (12 years). Data included histopathology reports. The tumors have been classifield and 
incidence estimated. A subgroup of this cohort ( Mestre, Mirano, Treviso) was evaluated in term of 
clinical outcomes, follow-up and surgical success, defined as disease-free survival.  
 
Results:  
The study population included 279 patients, average age of 59.8±16.8 years (<1 year to 83 years), 
female gender in 55.6% (155 women). The incidence of primary cardiac tumors in Veneto Region 
was constant every years (0.47%) and the distribution per age showing a peak of incidence in 
people 60–70 years of age (n=75, 26.88%). 254 patients (91%) were affected by benign primary 
cardiac tumors and 25 (9%) patients by malignant cardiac tumors. Among the benign cardiac 
tumours group, the majority (70.08%) were myxomas, followed by papillary fibroelastomas 
(18.90%), lipomas (3.15%), hemangioma (2.76%), rhabdomyomas (0.79%), leiomyoma (0.79%) 
and fibroma (0.39%). In the malignant group the most prevalent histotype was angiosarcoma (n=8, 
32%), followed by lymphoma (n=6, 24%), leiomyosarcoma (n=3, 12%) and undifferentiated 
sarcoma (n=6, 24%).  Cardiac myxoma is the most frequent primary cardiac tumor in our surgical 
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series and his location was mostly in the left atrium (n=162, 91%), followed by the right atrium 
(n=16, 9%).  
The location of the second most frequent primary cardiac tumor (papillary fibroelastoma) was the 
valvular endocardium in 41 patients: aortic valve (n=23, 47.9%), mitral valve (n=13, 27.1%), 
tricuspid valve (n=6, 12.5%), and pulmonary valve (n=1, 2.1);  and the mural endocardium in 7 
patients (left ventricular cavity and right atrial cavity).  
Subgroup of general population was analyzed by processing clinical, surgical and follow-up data. 
Seventy-nine consecutive patients, 41 female (51.9%) and 38 male (48.1%), were referred for 
surgical resection of a cardiac mass at three Cardiac Surgery Institutions of the Veneto Region 
(Mestre, Treviso, Mirano). The median age was 63.3±15.2 years. All tumors were detected by 
transthoracic and transesophageal echocardiography. The incidence of benign neoplasms was much 
higher than malignant masses; of the benign tumors, 77.2% (n=61 patients) were myxomas. Of the 
malignant tumors, synovial sarcoma was the most common cardiac tumor (n=2 patients, 2.5%). The 
clinical pre-operative presentation was: dyspnea with NYHA Class II-III in 36.7% patients, chest 
pain in 29.1% and embolic complications in 8.8% of which 6.7% cerebral ischemic events. The 
location of the tumors was: 54.7% in the left atrium, 8.9% in the right atrium, 5.1% in the 
ventricles, 10.1% on the valves. Eleven patients underwent a mini-invasive surgical approach. Early 
(30 day) mortality was 1.2% (n=1), due to septic shock and multiorgan failure. Late mortality was 
10.1% (n=8). One malignant tumor (angiosarcoma) and one benign tumor (myxoma) recurred 
during follow-up requiring re-intervention.  
 
Conclusions:  
 
Epidemiological data of primary cardiac tumours are still based on post-mortem studies. The 
incidence and prevalence of cardiac neoplasms, in general, have shown little change over time. 
Surgical pathology started with the advent of cardiac imaging and open heart surgery when cardiac 
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neoplasms were diagnosed during life. The purpose of Veneto Registry is to discuss the actual 
prevalence and pathology of primary cardiac tumours.  
Histology with immunohistochemistry of any cardiac mass is mandatory for diagnosis, therapy and 
prognosis. The surgical results suggest that complete surgical resection of primary benign cardiac 
tumors is associated with very-good long-term survival and recurrence is rare. Immediate surgical 
treatment was indicated because of the high risk of embolization or of sudden cardiac death. 
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GENERAL SURVEY of CARDIAC TUMORS 
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CHAPTER 1 
 
 
 
INTRODUCTION 
 
 
Although the term tumour generally recalls the idea of “cancer”, at a cardiac level most primary 
tumours are biologically benign and malignancy is haemodynamic, due to obstruction of the blood 
flow because of intra-cavitary growth and embolism following neoplastic fragility with ischemic 
damage of distal organs (1-3).  
The first description of cardiac tumors was made by Matteo Realdo Colombo in 1559 in his book 
De Re Anatomica (1, 4-6). While performing the autopsy of Cardinal Gambaro from Brescia, while 
he was archiater in Rome at that time, Colombo discovered a left ventricular mass described as 
follows in Latin “In Cardinali Gambara Brixiano tumorem praedurum, et ad ovi magnitudinem in 
sinistro cordis ventricolo Romae vidi, ubi illum in affinium gratiam dissecarem” (“in Rome I saw a 
solid tumour, large like an egg, in the left ventricle of Cardinal Gambaro of whom I was committed 
by the Pope to make autopsy”). Most likely it was a post-infarction endocavitary apical thrombus 
rather than a true neoplasm.  
An atrial tumor that was thought to cause valvular obstruction was described in 1809 by Burns (7). 
The first series of cardiac tumors that matched what we now recognize as myxoma was reported in 
1845 by King (8). 
In 1931, Yates published 9 cases of primary cardiac tumors and established a classification system 
(9). All of these tumors were postmortem reports, with the first antemortem diagnosis reported in 
1934 by Barnes et al of a cardiac sarcoma with abnormal electrocardiogram and a metastatic lymph 
node that allowed tissue diagnosis (10). Surgical intervention with excision of a cardiac tumor was 
first reported with success, by Beck in 1942, involved removal of a teratoma external to the right 
ventricle (11). 
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The first book on cardiac tumours was published in 1945 by Ivan Mahaim, from the University of 
Lausanne with the title Les tumeurs et les polypes du coeur: etude anatomo-clinique (3) (Figure 
1.1). 
  
 
 
 
 
 
 
 
At the Institute of Pathological Anatomy of the 
peaceful Lausanne, the young cardiac pathologist 
Mahaim (Figure 1.2) wrote an extraordinary 
book, that was a collection of personal 
observations at postmortem as well as of 
literature review, and represented a milestone 
publication on the topic of cardiac tumors for 
several generations of pathologists and 
physicians involved in the field. From him we 
learned that cardiac myxoma (called in French 
“le polype” due to its resemblance to a 
pedunculated gastro-enteric polyp), can have a clinical presentation with syncope or dyspnea due to 
Figure 1.1 A) Title page of the book by Ivan Mahaim on cardiac tumors, published in 1945. B) 
Drawing of a left atrial myxoma in the book by Mahaim, described as a “pedunculated polyp” 
accounting for functional mitral stenosis. Mahaim I, Les Tumeurs et les Polypes du Coeur: Etude 
Anatomoclinique, 1945. 
 
Figure 1.2 Ivan Mahaim 
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atrio-ventricular valve orifice occlusion (functional mitral stenosis), with peripheral artery occlusion 
due to embolic phenomena, or can be totally asymptomatic being an incidental finding (“les polypes 
silencieux”). Although these were all autopsy cases, Mahaim was optimist on the perspectives of 
Medicine. While treating atrial myxoma (“Le polype du coeur”), the most frequent cardiac tumor 
(nearly two-thirds of primary heart neoplasms), he said “...surgical resection of atrial polyp 
encounters apparently unsurmountable difficulties. However, we should not give up because of this 
feeling. In any field of science, with technological progress, the impossible is just a moment during 
the evolution of our powers. As Mummery said about alpinism, the inaccessible peak becomes an 
easy route for ladies...” (1,3).  In fact, some years later the era of “surgical pathology” started with 
the advent of cardiac imaging and open heart surgery in the ‘60s, when cardiac neoplasms were 
diagnosed during life and not only in the autopsy room and became surgically resectable with 
excellent long-term survival (12,13).  
On the contrary, in 1951 Prichard (12) manifested a pessimistic attitude by saying “...of the surgical 
treatment of these tumours we never heard…” (3).  Surprisingly, in the same year 1951, Goldberg et 
al. (13) for the first time successfully made a clinical diagnosis of left atrial myxoma using 
angiography (14), and Maurer in 1952 reported the successful removal of a left ventricular lipoma 
(15). This paucity of surgical success changed because of 2 events: 1) the introduction of 
cardiopulmonary bypass (CPB) in 1953 by John Gibbon (16), allowing a safe and reproducible 
entry into the cardiac chambers, and 2) the introduction of echocardiography, allowing easy, 
noninvasive imaging of intracardiac structures and masses. Bhanson made an early attempt at 
removing an intracardiac right atrial myxoma in 1952 by using caval inflow occlusion, but the 
patient expired 24 days later (17). The first successful removal of an intracardiac tumor is generally 
credited to Crafoord from  Sweden, who in 1954 removed a left atrial myxoma using CPB (18). 
Progress from this point was rapid; by 1960, 60 successful cases of atrial myxoma removal had 
been reported, with increasing use of angiography for detection and CPB for removal (19). Today, 
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operation for benign cardiac tumors, although still uncommon, is generally carried out with low 
morbidity and mortality.  
However, the historical watershed in the diagnosis and treatment came in the 1980s, with the advent 
of non-invasive imaging, i.e., echocardiography which, together with computed tomography (CT) 
and cardiac magnetic resonance (CMR), substantially improved diagnosis and subsequent 
treatment. It is possible to easily visualize cardiac tumors at the first onset of symptoms or even 
incidentally, during routine echo diagnostic procedures, and send the patient promptly to the 
surgeon for resection with a nearly 100% success in the benign forms. Before the 1980s cardiac 
tumors were a postmortem finding, thereafter they became almost exclusively a clinical and surgical 
observation (20).  
The role of the pathologists is now to establish in vivo the nature of the resected mass (non-
neoplastic, benign, or malignant neoplasms) and to make the differential diagnosis with secondary 
neoplasms. The advent of immunohistochemistry to characterize the antigenic markers, by using 
monoclonal and polyclonal antibodies, leads to major advances in the diagnosis of primary and 
secondary cardiac tumors as in other fields of oncology, but particularly of malignant primary 
tumors, where the tumor cell of origin can be the endothelial cell, fibroblast, cardiomyocyte, smooth 
muscle cell, adipocyte. (1,21).  
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CHAPTER 2 
 
 
 
EPIDEMIOLOGY AND INCIDENCE 
 
The cardiac tumor is rarely encountered, and its incidence is very low compared to tumors of other 
organs. In the past, cardiac tumors were very difficult to diagnose before life and were often 
discovered incidentally at autopsy. Recent advances in diagnostic techniques such as 
echocardiography and CT enabled clinical diagnosis during lifetime, and pathological diagnosis of 
tumor can be obtained by surgically removed tumors or surgical/endomyocardial biopsy. By 
cumulate pathological and clinical data, it became evident that many varieties of tumors occur in the 
heart and great vessels as in other organs.  
 
 
 
2.1 The incidence of cardiac tumors at autopsy  
 
 
Epidemiological data of cardiac tumors are still based on postmortem studies (1,2). 
 
The referred prevalence is very low, ranging from 0.0017% to 0.33% in autopsy series, the 
variability being strongly influenced by when and where the data have been collected and according 
to diagnostic methods (1-6) (Table 2.1).  
Pollia and Gogol (7) reported the highest incidence of primary cardiac tumors as 0.33 % (154 cases) 
in 46,072 autopsy cases, while Straus and Merliss (9) reported the lowest incidence as 0.0017 % (8 
cases) in 480,000 autopsy cases. Reynen (10) reported the incidence as 0.021% in 731,309 autopsy 
cases by summarizing the autopsy data from literature. Reports on cardiac tumors in children are 
scarce, with a reported incidence at autopsy of 0.01% by Nadas and Ellison (12).  
At the Institute of Pathology of the University of Padua in the time interval of 1967–1976, on 7,460 
autopsies the prevalence of primary cardiac tumour was 1 out of 2,000 and that of secondary 
tumours was 1 out of 100 autopsies, with a secondary/primary ratio of 20:1 (Figure 2.1)(1,13, 14).  
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Table 2.1 Incidence of primary cardiac tumors diagnosed at autopsy. Modified from Wold LE, Lie 
JT. Cardiac myxomas: a clinipathologic profile. AM JPathol. 1980:101;219-40. 
 
Authors Autopsy cases Primary cardiac 
tumors 
Incidence(%) 
Pollia 7 46,072 154 0,33 
Benjamin8 40,000 12 0,003 
Straus 9 480,000 8 0,0017 
Reynen10 731,309 15,357 0,021 
Mayo clinic  
   Lymburner11:1912-1931 
   Wold3: 1954-1973 
 
8,550 
23,673 
 
4 
41 
 
0,047 
0,17 
 
 
Figure 2.1 Primary cardiac and pericardial tumours at the Cardiovascular Pathology Unit, 
University of Padua (1970-2004): total n. 210 cases. 
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2.2 Human cardiac tumors 
 
Cardiac and pericardiac masses include benign and malignant, both primary and secondary tumors, 
and nontumoral lesions. Concerning the epidemiology and prevalence of various histotypes, in the 
Armed Forces Instiute Pathology (AFIP) data (15), cardiac myxoma is the most common cardiac 
tumor accounting for 24–37% of them, following by papillary fibroelastoma (8.0%). According to 
the histological classification by the World Health Organization (5), among the benign cardiac 
tumors, the majority (63%) are myxomas, followed by papillary fibroelastomas (8%). 
Angiosarcoma, unclassified sarcoma, and malignant fibrous histiocytoma represent the main 
malignant primary cardiac tumors. In comparison with adults, the incidence of cardiac tumors in 
children is very low (12,15). With rate of rhabdomyoma and fibroma and histiocytoid 
cardiomyopathy also is relatively high, but cardiac myxoma is the most common histotype even in 
children (1,15,16). In children, malignant tumors originating from the heart are very rare, and 
leiomyosarcoma, unclassified sarcoma, and rhabdomyosarcoma (10,15).  
The age at diagnosis of cardiac tumors is different for each tumor subtype. According to the AFIP 
data (15), rhabdomyoma and teratoma occur in infancy, rhabdomyosarcoma and cardiac fibroma are 
common in the adolescence, myxoma, papillary fibroelastoma, mesothelioma and lipoma tend to 
occur in the elderly (1, 15,17). The data reported by the AFIP (15) are questionable, since AFIP 
achieve a precise diagnosis as a tertiary international center for consultancy of difficult cases. 
 
2.3 Secondary (metastatic) cardiac tumors  
 Metastatic cardiac tumors are more frequent than primary cardiac malignant tumors (1,2,18-20), 
with  a ratio of cardiac metastases to primary malignant tumors 100:1 to 1,000:1 (15). The rates of 
cardiac metastasis reported in the literature are highly variable (Table 2.2).  
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Table 2.2 Reported incidences of metastatic cardiac tumors in the literature. Modified 
from Basso et al., Cardiac Tumor Pathology, 2013. 
 
  
Author Neoplasms 
N. 
Cardiac Metastases 
N. (%) 
Walther 21 2,027 46 (2,3) 
Wills 22 342 17 (4,9) 
Hanfling 23 694 127 (18,3) 
Berge &Sievers 24 2,595 122 (4,7) 
Kline 25 716 61 (8,5) 
Karwinski & Svendsen 26 2,564 130 (5,1) 
Mukai et al. 27 6,240 953 (15,0) 
Manojlovic 28 477 39 (8,2) 
MacGee 29 1,311 57 (4,3) 
Silvestri et al. 30 1,928 162 (8,4) 
Bussani et al. 20 7,289 662 (9,1) 
 
Mukai et al. (27) reported that during a 10-year period (1976–1985), only one case of a primary 
pericardial malignant mesothelioma (0.038%) was identified among 2,649 autopsies of malignant 
tumors at the National Cancer Center Hospital, in contrast, there were 407 cases (15.4%) in which 
heart and/or pericardium were secondarily involved with a malignant tumor from other organs. 
Butany et al. (31) reported two primary malignant tumors originated from the heart (0.017%) and 
264 metastatic (2.31%) among 11,432 autopsies (with a ratio of primary malignant to metastatic 
tumors 1:132). Bussani et al. (19) reported 662 cases among 7,289 autopsy cases with malignancies 
(9.1%), with a decreasing occurrence with age (16.8% in people <64 vs 8.5% in people >85), 
probably due to less biological aggressiveness in the elderly.  
In a consecutive surgical pathology series of 210 primary cardiac neoplasms studied at the 
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University of Padua, 89% were benign and 11% malignant. The collected data in Padua are much 
more reliable since they are a consecutive surgical series covering 35 years span (32) ( Figure 2.1).  
Any extracardiac malignant tumour may metastasise to the heart, however, melanoma, lung and 
breast carcinoma show the highest cardiotropism, reflecting also the most common incidence of 
these cancers.  The sites of the metastatic tumor in the heart are the myocardium, the pericardium, 
and both myocardium and pericardium. Mukai et al. (27) reported that among 407 cases of cardiac 
metastasis, metastasis to the myocardium were 169 cases (41.5%), followed by epicardium 136 
cases (33.4 %), pericardium 78 cases (19.2%), and endocardium 24 cases (5.9%). Butany et al. (31) 
reported that among 193 cases of cardiac metastasis, metastasis to the pericardium were 127 cases 
(65.8%), myocardium 56 cases (29.0%), epicardium 48 cases (24.9%), and endocardium 6 cases 
(3.1%) (Table 2.3). Formerly, most of the metastatic cardiac tumors have been so far reported in 
autopsy cases. Recent advances of diagnostic imaging methods by CT, CMR, and echocardiography 
enabled to discover metastasis to the heart early even in the absence of symptoms related to the 
heart, such as arrhythmia and heart failure (33).  
Table 2.3 Metastatic sites of the heart and the pericardium. Modified from 
Amano J. et al. Textbook of cardiac tumors, 2011.  
Sites Mukai27 Butany 31 
Heart/pericardium 407 264 
Heart: with or without 
pericardial involvement 
329 137 
Pericardium only 78 127 
Extent of involvement 
   Pericardium 
   Epicardium 
   Myocardium 
   Endocardium 
 
78 (19,2%) 
136 (33,4%) 
169 (41,5%) 
4 (5,9%) 
 
127 (65,85) 
48 (24,9%) 
56 (29,0%) 
6 (3,1%) 
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CHAPTER 3 
 
 
 
CLASSIFICATION OF TUMORS OF THE HEART AND GREAT VESSELS 
 
Among tumors of the heart and great vessels, about 90% of the surgically excised tumors are benign 
(1-3). Since there is lack of histogenetical and pathological evidence of true neoplastic nature for 
papillary fibroelastoma, histiocytoid cardiomyopathy, lipomatous hypertrophy of the interatrial 
septum or cystic tumor of atrioventricular node, pathological classification is very difficult for these 
tumors (4). Moreover, because origin and cell differentiation of many cardiac tumors is not yet 
determined, it is very difficult to classify over on thid thesis. According to the well-known 
classification of ‘‘Tumors of the heart and great vessels’’ (Armed Forces Institute of Pathology: 
AFIP) published in 1996 (5) (Table 3.1), cardiac tumors, including both cardiac tumors and 
pericardial tumors, are classified into benign and malignant. Sarcomas of the aorta and pulmonary 
artery, sarcomas of the inferior vena cava, and leiomyomatosis of veins are classified in different 
categories. Benign cardiac tumors are further classified as tumors of unknown histogenesis, tumors 
of cardiac muscle, tumor of fibrous tissue, vascular tumors and tumor-like lesions, tumors and 
proliferations of fat, tumors and tumor-like lesions of mesothelial cells, tumors of neural tissue, 
tumors of smooth muscle, and tumors of ectopic tissue. Malignant cardiac tumors are classified as 
sarcomas, malignant germ cell tumors, hematologic tumors, mesothelial malignancies, and 
metastatic tumors to the heart.  
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Table 3.1 Classification of ‘‘Tumors of the heart and great vessels’’ (Armed Forces 
Institute of Pathology: AFIP). From Burke A, et al.,Tumors of the heart and great vessels. 
Atlas of tumor pathology, 1996. 
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In the 2004 WHO classification, tumor of the heart are divided into three categories: benign tumors 
and tumor-like lesions, malignant tumors, and pericardial tumors (6) (Table 3.2).  
 
Table. 3.2 2004 WHO classification of tumors of the heart. From Burke 
AP, et al., Tumors of the heart. In: Travis WD, et al., JARC Press; 
2004.  
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Benign tumors were classified as tumor showing differentiation into muscle cells, such as 
rhabdomyoma, adult cellular rhabdomyoma, hamartoma of mature cardiac myocytes, and 
histiocytoid cardiomyopathy. Cardiac myxoma and papillary fibroelastoma are classified as 
pluripotent mesenchymal tumors, and cardiac fibroma and inflammatory myofibroblastic tumor as 
tumor showing differentiation into myofibroblastic cell. This classification does not include benign 
cardiac tumors with low incidence such as tumors of neural cell or smooth muscle cell 
differentiation. Most prominent differences of 2004 WHO classification from AFIP classification 
are malignant tumors. First, epithelioid hemangioendothelioma, formerly considered a benign 
tumor, has been classified as malignant tumor; undifferentiated sarcoma, previously classified as 
tumor of unknown origin, is part of malignant pleomorphic fibrous histiocytoma (MFH)/ 
undifferentiated pleomorphic sarcoma subtype. Moreover, in the 2004 WHO classification, 
malignant mesenchymoma, osteosarcoma, chondrosarcoma, and many other sarcomas, are 
considered as independent sarcoma, and myxosarcoma as a subtype of myxoid fibrosarcoma.  
Recently, a new WHO classification has been published, taking into account the recent findings on 
cell differentiations and molecular basis of cardiac tumors (7) (Table 3.3).  
Tumors are classified as benign tumors, tumors of uncertain biologic behavior, germ cell tumors, 
malignant tumors and tumors of the pericardium (8). The major changes in tumors of the heart have 
been: the removal of the term ‘malignant fibrous histiocytoma’ as synonymous with 
undifferentiated pleomorphic sarcoma; incorporation of epithelioid hemangioendothelioma as an 
angiosarcoma with low-grade malignance; remarkable expansion of the cytogenetic and molecular 
genetic characterization of many cardiac tumors; re-introduction of the primary cardiac 
osteosarcoma and myxofibrosarcoma subtypes. The clinical-pathological entity referred to as 
intimal sarcomas has been not included in the new WHO classification (9). Intimal sarcoma has 
been recently reported in the heart as the most frequent sarcoma histotype (10). As in large vessels, 
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this type of sarcoma is characterized by overexpression of  MDM2 as well as alterations in genes 
like PDGFRA and EGFR that could be targets for novel therapeutic approaches.  
Table 3.3 2004 WHO classification of tumors of the heart. From Travis WD, et 
al., WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 
2015. 
 
     ICD-O, International Classification of Diseases for Oncology; NOS, not otherwise specified. 
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Table 3.4 Clinicopathologic Features of primary Heart Tumors. From Travis WD, et al., WHO 
Classification of Tumours of the Lung, Pleura, Thymus and Heart, 2015. 
 
 
aBoldface indicates an exclusive site. 
bHemangioma is considered alternatively as a congenital tumor, especially in children. 
cEspecially the capillary type. 
dInflammatory myofibroblastic tumors are sometimes considered low-grade malignancies, although 
none in the heart has metastasized.WHO, World Health Organization; AV, atrioventricular; SA, 
sinoatrial; LA, left atrium; RA, right atrium; UPS, undifferentiated pleomorphic sarcoma.  
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Figure 3.1 Osteosarcoma, left atrium. (A) Autopsy specimen (cut open, four-chamber view) shows 
an infiltrative, pale and gritty mass (asterisk) centered in the left atrium with contiguous mitral 
valve invasion (arrow). (B) Some areas were myxoid and relatively bland, similar to 
myxofibrosarcoma. (C) The bone formation in this invasive area of tumor (into the pulmonary vein) 
showed well-differentiated osteoid. (D) In some areas, there is chondrosarcoma. (E) Other areas 
show poorly differentiated osteosarcoma. From Burke A, Journal of Thorac Onc, 2015. 
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CHAPTER 4 
 
CLINICAL MANIFESTATIONS OF CARDIAC TUMORS 
 
 
The clinical manifestations of cardiac tumors are protean (1). They produce symptoms by their 
mass effect, local invasion, embolization, or sytemic constitutional manifestations and must be in 
the differential diagnosis of any patient who presents with one or a combination of the following 
symptoms (2). 
 
Pericardial Involvement  
Neoplastic infiltration of the pericardium can produce pericarditis with resultant haemorragic 
effusion and tamponade. In addition, pericardium can become non-compliant resulting in a clinical 
presentation indistinguishable from constrictive pericarditis of infectious or idiopathic origin.    
 
Congestive Heart Failure  
The mass effect of an intracavitary tumor can obstruct the transfer of blood through the cardiac 
chambers or can interfere with the normal coaptation and opening of the cardiac valves (Figure 
4.1). Depending which chambers or valves are involved, the patient may present with syncope, 
angina, dyspnea, edema, ascites, or any combination of murmurs indicative of valve stenosis or 
incompetence. In addition, neoplastic involvement of the myocardium may impede myocardial 
pump function resulting in a presentation of congestive heart failure similar to a cardiomyopathy.  
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Figure 4.1 Transesophageal echocardiography. Reprinted with permission of the Italian Society of 
Cardiology. Large left atrial myxoma attached to the interatrial septum, prolapsing in diastole 
through the mitral valve. From Basso C, et al., Cardiac Tumor Pathology, 2013. 
 
 
 
 
Pulmonary Hypertension  
Elevated pulmonary artery pressures can be caused by obstruction of the pulmonary arteries by 
tumor emboli, but more commonly is a result of pulmonary venous hypertension due to obstruction 
to left heart filling.  
 
Embolization  
Systemic emboli from left heart lesions, in particular left atrial myxoma, are much more frequentl 
than pulmonary tumor emboli from right heart lesions.  
 
Arrhythmia  
Atrial fibrillation, one the most important arrhthmia Atrium may be a direct manifestation of 
primary neoplasms, metastatic cardiac tumors or tumors of adjacent tissues, such as the lungs and 
esophagus that invade the heart (3). Certain patients with cardiac tumor manifest only recurrent 
supraventricular or ventricular arrhythmias, most likely due to the irritative effect of tumor invading 
cardiac muscle. More rarely, the conduction system is injured resulting in heart block and Stokes-
Adams attacks.  
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Chest Pain  
Pain is a common manifestation of malignant tumors, but instances of ischemic cardiac pain due to 
tumor embolization to the coronary arteries (4) or extrinsic compression of myocardial vessels have 
been also reported (5). 
 
Constitutional Symptoms  
Fever, malaise, weight loss, Raynaud's phenomenon, hyperglobulinemia and an elevated 
erythrocyte sedimentation rate have all been described in both benign and malignant lesions but 
most frequently are associated with left atrial myxomas. The etiology of these phenomena is 
speculative. The leading theories postulate either an autoimmune or a systemic response to altered 
serum proteins damaged by tumour movement and to tumor breakdown products released into the 
circulation because of necrosis or hemorrhage. The hyperglobulinemia is always polyclonal and is 
completely reversible after tumor resection (6). There are no qualitative, just quantitative serum 
protein abnormalities. The elevated globulins probably explain the concomitant elevated 
erythrocyte sedimentation rate.  
 
Hematologic Abnormalities  
The hemolytic anemia and thrombocytopenia, again often noted in left atrial myxomas, are plied to 
be due to the mechanical destruction of these blood elements by a mobile intraluminal tumor (7). 
Polycythemia is seen on occasion with right atrial tumors and most likely represents the response to 
hypoxia when the tricuspid valve is obstructed with subsequent elevation of right atrial pressure, 
stretching of the foramen ovale, and right to left shunting (8).  
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4.1 Common Clinical Manifestations of Benign tumors   
 
Patients are frequently asymptomatic and the tumor is found as an incidental finding on two-
dimensional echocardiography.  
When symptoms are present, dyspnea, especially dyspnea that is worse while lying on the left side, 
should alert to the possibility of a myxoma. Most signs and symptoms related to myxoma result 
from obstruction of the mitral valve (syncope, dyspnea, and pulmonary edema), followed by 
embolic manifestations (9). Patients may also have nonspecific symptoms such as fatigue, cough, 
low-grade fever, arthralgia, myalgia, weight loss, and erythematous rash, as well as laboratory 
findings of anemia, increased erythrocyte sedimentation rate, and increased C-reactive protein and 
gamma globulin levels. Less commonly they may have thrombocytopenia, clubbing, cyanosis, or 
the Raynaud phenomenon.  
Findings on physical examination can reveal a systolic murmur or a diastolic murmur suggestive of 
mitral stenosis. A tumor plop may also be present (a low-pitched diastolic sound heard as the tumor 
prolapses into the left ventricle). In one study a cardiac auscultation abnormality was detected in 
64% of the patients (10); the most common abnormal auscultation finding is a systolic murmur (in 
50% of cases), followed by a loud first heart sound, an opening snap, and a diastolic murmur. A 
systolic murmur may be caused by damage to the valves, failure of the leaflets to coapt, or 
narrowing of the outflow tract by the tumor. A diastolic murmur is due to obstruction of the mitral 
valve by the myxoma. Tumor plop may be confused with a mitral opening snap or a third heart 
sound and can be detected in up to 15% of cases (10).  
Chest examination may reveal fine crepitations consistent with pulmonary edema.  
Examination of the extremities may also reveal signs of an embolic phenomenon and the signs vary 
depending on the vascular territory. Involvement of the cerebral vessels results in neurologic signs, 
involvement of the coronary arteries may result in an acute coronary syndrome, intestinal arterial 
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obstruction may result in an ischemic bowel, and peripheral arterial obstruction can result in limb-
threatening ischemia.  
 
4.2 Common Clinical Manifestations of Malignant Tumors  
 
Malignant primary cardiac tumors commonly cause symptoms by three separate mechanisms: 
obstruction, embolization, and arrhythmias. Pericardial invasion and tamponade may be rarely the 
first manifestation of the disease. Both atrial and ventricular tumors, when large enough, may result 
in obstructive symptoms and cause syncope, chest pain, dyspnea, or heart failure.  
The most common initial symptom is dyspnea, followed by chest pain, cough, syncope, hemoptysis, 
sudden death, fever, embolic events, and cardiac arrhythmias (11). Tumors infiltrating the 
ventricular wall might damage the myocardium or conduction system and result in ventricular 
arrhythmias. Conduction disturbances caused by myocardium invasion would lead to arrhythmia, 
such as premature beats or atrial fibrillation (12).  
Large tumors on the right side, in addition to causing venous congestion, may also limit cardiac 
filling and result in sudden decreases in intravascular volume, thereby potentially precipitating 
syncope in these patients. Left-sided cardiac tumors, if large enough, can also impair ventricular 
filling and lead to syncope or heart failure.  
Unfortunately, approximately 29% of cardiac sarcomas are found to have metastatic disease at 
initial evaluation, typically in the lung (11). Sarcomas, especially left-sided ones, are commonly 
associated with cardiac embolic events, (13) and arrhythmia can be an important problem as well. A 
finding of a cardiac mass with pericardial effusion should raise suspicion for a malignant cardiac 
tumor (14). It might be expected that the pericardial effusion associated with a malignant primary 
tumor is due to associated pericardial involvement; however, a malignant effusion is not always 
present.  
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CHAPTER 5 
 
 IMAGING 
 
Cardiac masses frequently present significant diagnostic and therapeutic clinical challenges. In 
many cases a cardiac mass is detected as an incidental finding and the resultant evaluation may 
culminate in confirmation of a cardiac tumor, which generally is an uncommon event because other 
cardiac masses, such as thrombus or vegetation, are generally much more common.  
 
5.1 Initial Decision Making  
It is interesting to note that patients with cardiac tumors may initially have no symptoms or physical 
findings but exhibit abnormalities on imaging. Alternatively, there may be a host of nonspecific 
symptoms or findings on physical examination, and of course, there may be very specific and 
detailed symptoms or signs that should alert physicians to the possibility of a cardiac tumor (Table 
5.1) (1,2). The most important consideration in confirming the presence of a cardiac tumor is a high 
index of suspicion and integration of the symptoms, findings on physical examination, and imaging 
characteristics in a logical way to establish a clinically reasonable plan of action. Primary tumours 
of the heart and pericardium may be detected as an abnormal finding on a chest radiogram or 
another imaging test obtained for an unrelated reason. Taking into account the likelihood of cardiac 
tumors the diagnostic procedures should be performed in all patients with unexplained cardiac 
murmurs, congestive heart failure, arrhythmias, which are accompanied fever, anemia and weight 
loss of unknown cause. In such cases the basic laboratory tests should include tumor markers. 
Cardiologic diagnostic procedures should be widened with particular emphasis on imaging 
methods.  
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Table 5.1 Range of clinical findings that may indicate a cardiac 
tumor. Modified from Braunwald's Heart Disease, 2015. 
 
Clinical findings that may indicate a cardiac tumor 
Completely asymptomatic but an incidental abnormality on 
imaging 
Low-grade fevers 
Transient ischemic attack or cerebral vascular event 
Positional dyspnea 
Weight loss 
Peripheral embolic events 
Chest discomfort 
Congestive heart failure 
Upper extremity or neck swelling 
Lower extremity venous thrombosis 
Palpitations 
Arrhythmias 
Pericardial effusion/tamponade 
 
 
Once detected, cardiac imaging is needed to define tumour location, extent and boundaries; 
relationships with adjacent key cardiac structures such as valves and coronary arteries; tumour type; 
and presence and degree of functional impairment. 
The initial evaluation is typically an imaging test such as two-dimensional echocardiography (3) or 
magnetic resonance imaging (MRI) (4) by which a mass is identified. Depending on the 
characteristics of this mass and the known comorbid conditions of the patient, additional imaging 
may be undertaken, including three-dimensional echocardiography with contrast enhancement (5), 
MRI with gadolinium (6,7), coronary angiography to define the presence of coronary artery disease 
(8), position emission tomography (PET) to provide staging for cancer, or computed tomography 
(CT) to clarify intrathoracic structures (9,10). Transesophageal echocardiography (TEE) can also 
provide very specific anatomic information that is critical to planning treatment (8) (Table 5.2).  
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Table 5.2 Common testing that may indicate the possibility of a 
cardiac tumor. Modified from Braunwald's Heart Disease, 2015. 
 
 
Imaging Test 
Two- or Three-dimensional echocardiography 
Chest radiography 
Computer tomography 
Magnetic resonance imaging 
Transesophageal echocardiography 
Position emission tomography 
Nuclear scintigraphy 
 
 
When assessing a cardiac mass as initial evaluation for a cardiac tumor, the clinical context in 
which the image was obtained is critical because the differential diagnosis of a cardiac mass is 
broad and includes tumors, thrombi, infection, and artifacts (Table 5.3).  
Table 5.3 Differential diagnosis of cardiac masse. Modified from 
Braunwald's Heart Disease, 2015. 
Differential Diagnosis 
Intracardiac thrombus 
Focal myocardial hypertrophy 
Left ventricular noncompaction 
Infectious (abscess) 
Primary cardiac tumor 
Secondary cardiac tumor (metastasis) 
Lipomatous hypertrophy of the septum 
Cyst 
Imaging artifact 
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For example, if two-dimensional echocardiography shows an apical mass in a patient with new-
onset heart failure, a cardiac tumor is less likely (11). The presence of a severe wall motion 
abnormality, as well as the fact that the mass may appear distinct from the myocardial wall and is 
lobulated, strongly suggests that the mass is much more likely to be a thrombus than a tumor 
(Figure 5.1). Another scenario involves a patient with a history of melanoma that is metastatic to 
other organs and on routine cardiac imaging a solid mass is seen in an unusual location. Because 
there is no wall motion abnormality and no significant valvular disease or clinical signs suggestive 
of infective endocarditis, this mass is very likely to be a metastatic lesion to the heart (Figure 5.2).  
 
Figure 5.1 Transthoracic color-Doppler echocardiography. Vascularized apical thrombus. Upper 
panel: epicardial tract of the left anterior descending (LAD) coronary artery visualized by color-
Doppler and the corresponding pulsed Doppler tracing with the characteristic anterograde sys- 
tolic and diastolic flow. Lower panel: vascularized apical thrombus with flow directed away from 
the transducer. From Basso C, et al., Cardiac Tumor Pathology, 2013 
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Figure 5.2 Two-dimensional echocardiography, apical four-chamber projection. Reprinted with 
permission of the Italian Society of Cardiology. Metastatic melanoma infiltrating almost entirely 
the right ventricle, and prolapsing in systole through the tricuspid valve. From Basso C, et al., 
Cardiac Tumor Pathology, 2013 
  
 
 
A common consideration that may suggest a tumor, in regard to imaging, is movement of the mass 
and related structures during a motion image. If a tumor is infiltrating the myocardium, the involved 
myocardial area will not contract in normal fashion. A left ventricular myocardial apical mass 
contracting similar to that of surrounding tissue is likely to be either focal hypertrophy or left 
ventricular noncompaction (12,13)  as opposed to a cardiac tumor.  
Furthermore, progression of an image over time may also indicate the pathologic process. If a 
cardiac mass changes in size from one image to the next, suspicion of a cardiac tumor is much 
higher. However, if an apical mass is stable for months or years, it is very unlikely to be a cardiac 
tumor. Of course, the exact nature and location of a mass are critical in determining whether it is 
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likely to be a tumor (14). A classic example of this principle is lipomatous hypertrophy of the intra-
atrial septum (Figure 5.3). The initial suspicion might be a myxoma or other tumor, but TEE 
revealing specific characteristics that are a hallmark of lipomatous hypertrophy will confirm the 
diagnosis (15,16). 
The main non-invasive imaging modalities for evaluating primary cardiac tumours each have 
advantages and disadvantages. They are often used together in a complementary manner for 
diagnosis and surgical planning (17). 
 
Figure 5.3. Lipomatous hypertrophy of the interatrial septum. Transesophageal echocardiography 
shows the typical thickening of the interatrial septum (Lip) that spares the region of the fossa ovalis 
(arrow) giving the classic dumbbell appearance to the interatrial septum. From Basso C, et al., 
Cardiac Tumor Pathology, 2013 
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ECG may not indicate any change, and some ECG features found in patients with cardiac tumor are 
usually nonspecific. It has been reported, that tumors of the heart are associated with shortening of 
P-R interval, the right or left bundle branch block (RBBB or LBBB) or complete heart block (18). 
There may also occur recurrent supraventricular tachycardia (19).  
Standard chest radiography may not reveal any changes. Uncharacteristic enlarged heart contour 
following a tumor appears in connection with heart failure. Asymmetrical enlargement of the heart 
may occur when the tumor is located within the anterolateral wall of left ventricle. Calcifications 
are rare, usually in the case of myxoma or fibroma. Pericardial effusion as the only radiological 
indicator of cardiac tumor (19,20).  
 
5.2 Echocardiography  
 
The primary advantage of echocardiography is that it has the best spatial and temporal resolution 
and provides excellent anatomic and functional information (21). It is the optimal imaging modality 
for small masses (<1 cm) or masses arising from valves (Figure 5.4)(22). A second major 
advantage of echocardiography is the ability to image velocities with Doppler, which allows for 
assessment of presence, degree, and location of obstructions to blood flow or valve regurgitation. 
Echocardiography is typically the modality used for the initial evaluation of cardiac tumours and 
may be the only diagnostic test required in some patients. Disadvantages include suboptimal image 
quality in patients with poor acoustic windows, inability to image extent of disease outside of the 
mediastinum, and relatively low soft tissue contrast, which limits detection of tumour infiltration 
and characterization of tumour tissue. Also, intravenous contrast agents are not routinely used with 
echocardiography, which limits the ability to characterize tumour vascularity (23). Although 
transthoracic echocardiography is simpler quieter and usually can identify a tumor, transesophageal 
echocardiography (TEE) may be more informative. 
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Figure 5.4 (a) A large right atrial myxoma attached to inter-atrial septum. Areas of calcification 
(arrow) and echolucencies (dashed arrow) can be appreciated within this polypoid mass. (b) A 
large right atrial mass (arrow) attached to the interatrial septum, associated with a second smaller 
mass attached to the left side of interatrial septum (arrow), that were found to be myxomas at 
pathological examination. LA left atrium, LV left ventricle, RA right atrium, RV right ventricle. 
From Basso C, et al., Cardiac Tumor Pathology, 2013.  
 
 
 
The superior diagnostic utility of TEE is due to the proximity of the esophagus to the heart, the lack 
of intervening lung and bone, and the ability to use high-frequency imaging transducers that afford 
superior spatial resolution (24). Fetal echocardiography allows for early diagnosis of cardiac 
embryonic tumor (25).  
 
5.3 Magnetic Resonance Imaging (MRI)  
 
The primary advantage of MRI is its excellent soft tissue contrast which makes it the most sensitive 
modality for detection of tumour infiltration. MRI has more manipulable imaging parameters than 
other imaging modalities. Because of this, MRI is the best modality for characterizing tumour 
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tissue. For example, a T2-weighted standard or fast spin echo sequence distinguishes tumours with 
high water content, such as haemangioma, from tumours with low water content, such as fibroma. 
A third advantage of MRI is the ability to characterize tumour vascularity with intravenous contrast. 
Though not as flexible as echocardiography, MRI does allow assessment of wall motion and 
assessment of velocities through large vessels. This allows for characterization of ventricular 
function, inflow or outflow obstruction and valve regurgitation. The primary disadvantage of MRI 
is long examination times, which translates into the need for sedation in children, and the need for 
reliable ECG gating. MRI should be considered when the tissue type, exact location, or the 
relationships of the tumour with neighbouring structures are not completely defined by 
echocardiography and when surgical resection of the tumour is considered (26-28). 
 
5.4 Computed Tomography (CT)  
 
ECG gated CT scans with the latest generation of multidetector scanners or with electron beam 
scanners are also very useful for cardiac imaging. In many ways, the advantages and disadvantages 
of CT are intermediate between those of echocardiography and MRI. Modern CT scanners have 
excellent spatial resolution, which is better than that of MRI, but not as high echocardiograpy. CT 
has better soft tissue contrast than echocardiography, and can be used to definitively characterize 
fatty content and calcifications; however, the overall soft tissue contrast and ability to characterize 
tumour infiltration and tumour type is less than that of MRI. Intravenous contrast can provide 
information about tumour vascularity, an advantage CT shares with MRI. CT may be used as an 
adjunct to both echocardiography and MRI. Positron emission tomography (PET) may be useful in 
identifying cardiac involvement in patients with metastatic tumors, atrial myxoma, or lipomatous 
septal hypertrophy (29-31).   
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5.5 Cardiac Angiography  
Coronary angiography is performed to assess the vascularity the tumor and its infiltration of the 
coronary arteries. This is of a particular importance in making the decision about surgery and the 
choice of it’s techniques. Cardiac catheterization provides additional information about the 
hemodynamic consequences of the presence of the tumor of the heart (32).  
Angiography provides indirect and nonspecific imaging based on filling defects within the cardiac 
chambers and displacement of the coronary arteries (32). Two exceptions are worth noting. First, 
endomyocardial biopsy for tissue typing may be considered in selected patients. Second, selective 
coronary angiography is helpful when planning surgical resection of an intramyocardial tumour.  
 
5.6 Transvenous Endomyocardial biopsy  
Intracardiac tumors are generally diagnosed by transthoracic echocardiography, transesophageal 
echocardiography and, more recently, magnetic resonance imaging. However, these techniques do 
not permit a histopathologic diagnosis. When surgery is not indicated because of limited 
hemodynamic changes but the benign nature of the tumoral mass is questionable, percutaneous 
transvenous biopsy, when technically feasible, may represent an alternative approach (33). The first 
reported use of TEE-guided intracardiac biopsywas by Scott and associates (34). A mass was 
embedded within the posterolateral wall of the right atrium, adjacent to the tricuspid annulus, and a 
percutaneous right femoral vein approach was used. This transvenous endomyocardial biopsy have 
the limit that are data available on the risks and benefits of transvenous biopsy of suspected cardiac 
tumors. Because myxomas may embolize, transvenous biopsy is not generally warranted if the 
appearance is typical on noninvasive imaging. Biopsy is considered reasonable for other cardiac 
tumors if potential benefits are deemed sufficient to outweigh potential risks.  
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CHAPTER 6 
 
BENIGN PRIMARY CARDIAC TUMORS 
 
Most (about 90%) primary cardiac tumors are benign, (1-7). Myxoma constitutes about 70-75% of 
all benign cardiac tumors in adults, but only a small percentage of such tumors in children (4). 
Rhabdomyoma is reported as the most common benign tumor in children (4,5). Other benign 
cardiac tumors that have been described include fibromas, lipomas, hemangiomas, papillary 
fibroelastomas, cystic tumors of the atrioventricular node, and paragangliomas.  
 
6.1 Cardiac Myxoma 
Cardiac myxomas represent the most common primary cardiac tumors (1,2,6-11). They are mainly 
localized to fossa ovalis on the left atrium and in up to 5% of cases overriding it and apparently 
looking as a biatrial tumor (10,11). Cardiac myxomas are usually single tumors, but rarely they can 
be multiple and familial as part of Carney complex (12-18).  
They have uncertain histogenesis and show a wide range of clinical presentations that may mimic a 
variety of neoplastic and nonneoplastic conditions (19-21). The tumor characteristics, together with 
possible tumor relapse following incomplete surgical resection, have contributed to the 
controversial issue of malignant myxomas or metastatic potential of cardiac myxomas (22,23). 
Several histological, cytogenetic, and molecular studies have been investigating their pathological 
and biological characteristics, including mechanisms of growth and embolic potential, and 
increasing evidences are confirming the benign byology of cardiac myxoma. Modern histological 
criteria and diagnosis tools (i.e. immunohistochemistry and molecular biology) are helpful for 
differential diagnosis from myxoid sarcomas that may share similar gross features but have 
malignant behavior and often poor prognosis (22,23).  
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Epidemiology 
 
Myxoma show a female preponderance, with F/M ratio of 1,8/1, a mean age at diagnosis of 50 
years, most patients being in 30-60 age range (10, 22, 24). Nevertheless they are reported also in 
pediatric age, and as a part of a genetic disease (i.e. Carney complex), diagnosed in young patients 
without sex predilection (14-18, 25).  
 
Macroscopy and histopathology 
 
Cardiac myxomas are intracavitary masses that occur most often in the left atrium (Figure 6.1). 
They arise from the endocardium of the atrial septum near the fossa ovalis in 85-90% of cases. Most 
of the remainder is located in the right atrium. Rarely, they arise in the ventricles.   
Multiple tumours occurring at sites other than fossa ovalis and ventricles are generally found in the 
inherited form of cardiac myxoma. Very rarely cardiac myxomas have also been documented to 
occur on valves and chordae tendineae.  
The external appearance, consistency, size and weight are extremely variable. They may be as small 
as a few millimeters and as large as 14 cm in diameter. The weight ranges are from 2-250 gm. Tiny 
cardiac myxomas may be totally asymptomatic and discovered incidentally at surgery for another 
purpose or autopsy. Larger ones are either sessile or pedunculated, but the site of attachment is 
always discrete and usually in the region of the fossa ovalis. Occasionally, the stalk may be long, 
resulting in free mobility of the tumour within the atrial cavity. 
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Figure 6.1 Left atrial endocavitary mass (A and B) Two-dimensional echocardiography, 
parasternal long-axis view (systole and diastole): note the diastolic tumour prolapse and the left 
atrial mass attached to the fossa ovalis; (C) gross examination of the surgically resected mass: note 
the polylobulated, myxoid appearance variegated in colour; (D) histology: note the typical villous 
appearance with stellate cells in a myxoid background, in keeping with a diagnosis of myxoma. 
From Basso et al., Heart, 2016. 
 
 
 
 
Myxomas are ovoid, globular, lobulated or polypoid. They may be smooth and glistening or have 
multiple papillary, villous, finger-like projections. They may be grey white and fibrous, gelatinous 
and myxoid, or a combination of both. The papillary structures may be quite friable increasing the 
risk of embolisation. Superficial thrombi also embolize. Marked variation in colour is distinctive. 
Pale grey, pearly white or yellow brown areas are frequently admixed with haemorrhagic dark 
brown or red areas. Tumour consistency depends on the quantity and distribution of fibrous tissue, 
and calcification. Rarely, the bulk of the tumour becomes calcified, so-called lithomyxoma (26).  
Histologically, cardiac myxoma is made up by a mucopolysaccharide-rich matrix conferring the 
typical myxoid aspect and numerous thin-walled blood vessels together with characteristic myxoma 
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lepidic cells. indicating (see ancient Greek lepis term) the scale-like cell shape. Lepidic cells are 
stretched or star-shaped, showing round or oval nucleus with often evident nucleolus.  They may be 
single, scattered cells or they constitute small nests, cord-like or perivascular structures. 
Perivascular structures are made up of single or multiple lepidic cell layer/s surrounding a central 
lumen with endothelial lining, with alcian-blue amorphous substance deposits between the lepidic 
cell layers. Associated features consist of hemorrhage, extramedullary hematopoiesis, inflammatory 
infiltrates (made up of granulocytes, lymphocytes, plasma cells, macrophages, and hemosid- erin-
laden macrophages), hemosiderin deposits, dystrophic calcifications (with possible Ghandi- Gamna 
sclerosiderotic areas and granulation tissue) and/or metaplastic ossification together with limited 
foci of necrosis. Calcifications may develop also within cell cords or pseudovascular cuffings, with 
characteristic stripe or ring shapes, both of them showing faded edges. Finally, the extracellular 
deposits of hemosiderin may develop a stretched structure, i.e., the so-called bamboo-shaped 
pattern. The myxoma pedicle is constituted by fibrous tissue with thick-walled vessels with possible 
medial and/or intimal hyperplasia. At tumor basis, myxoma may micrscopically infiltrate the 
adjacent endocardium and the underlying myocardium. Histologically, the infiltration is 
characterized by a stromal myxoid intercellular substance, which together with rare lepidic cells, 
pass through the cardiac myocytes and also in the medial arteriolar wall of the peduncle vessels 
(1,6). Within tumor, vessels of small and medium size (the latter ones usually are close to the base), 
and smooth muscle cells, localized to the media of blood vessels or in groups of cells interspersed in 
the myxoid stroma, are variably detected . 
 
Histopathogenesis 
The histogenesis of cardiac myxoma remains uncertain and different hypotheses have been 
formulated (27-29). This difficulty derives from the nature of morphological and 
immunohistochemical characterizations of this tumour. In fact, variable expressions of proteins 
typical of different adult cell phenotypes has been reported, even in the same cardiac myxoma, 
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suggesting an epithelial, endothelial, myogenic, myofibroblastic or neural origin (30-37). 
Phenotypic heterogeneity is also observed during cardiac development. In adult myocardium, two 
sarcomeric actins, α-cardiac (α-CA) and α-skeletal actin (α-SKA), are co-expressed and represent 
the predominant isoforms (38); in addition, α-smooth muscle actin (α-SMA) is transiently observed 
in cardiomyocytes during the early stage of fetal life (39). A possible explanation of  heterogeneous 
differentiation in cardiac myxoma is the origin from a pluripotential cell or from a subendothelial 
vasiform reserve cell (28,29). Although some morphological homologies between cardiac myxoma 
cells and those of embryonic cardiac cushion cells may support this hypothesis, available data 
remain scarce and inconclusive (40). The two main hypotheses suggesting an origin from 
multipotent mesenchymal cells or from neural endocardial tissue (27-41,42). Their preferential site 
(i.e. foramen ovale) is considered to be consistent with an origin from multipotent mesenchymal 
cells or from embryonic rests (42-44). Kodama et al (45) show a cardiomyogenic derivation of 
cardiac myxomas based on the finding of transcripts for Nkx2.5/Csx, typical of the cardiac 
homeobox gene, and consistent with a primitive cardiomyocytic phenotype. Other Authors have 
shown distinctive patterns and gene expression compatible with endocardial neural or embryonic 
tissue origin (27,46). Finally, Orlandi et al. in order to define the origin of this tumour have 
investigated the phenotype of cardiac myxoma cells in a large series of consecutive tumours with 
reference to the expression of actin isoforms and possible aspects of vascular differentiation. They 
reported the expression in tumour cells of transcripts characteristic of cardiac cushion development 
and/or primitive cardiac mesenchymal differentiation (27).  
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Neoplastic theory 
Cardiac myxoma is actually considered a neoplasm. It is histologically distinct from thrombus that 
may mimic cardiac myxoma. Many evidences are supporting the neoplastic hypothesis, either by 
showing a definitive pattern of differentiation, on the basis of cytological, ultrastructural, and 
immunohistochemical features, or demonstrating the biological characteristics by using 
experimental models such as in vitro cell cultures comparing thrombus and cardiac myxomas (47-
49).  
Thrombotic theory 
Development of cardiac myxomas from thrombus has been hypothesized (50). Myxomas apparently 
have show growth rate as mural intracardiac thrombus, often are partially covered by thrombotic 
depositions (similar to Lambl excrescences at gross examination) and share common features with 
organized thrombus (51). However, cardiac myxomas are characterized by the typical neoplastic 
lepidic cells and by a well-defined vascularization. 
Dysembryoplastic theory 
Cardiac myxoma has been supposed to represent a hamartoma originating from endocardial 
embryonic myxoid rests localized to foramen ovale (9). However, they are not present a birth, being 
usually diagnosed late in life, and do not spontaneously regress (12,13). 
Histopathogenesis of glandular cells in myxoma 
Glandular structures may be rarely found within an otherwise typical cardiac myxoma. 
Morphological and immunohistochemical studies support two hystopathogenetic hypotheses, that is 
a possible origin from embryonic foregut rests (52,53) or a progressive differentation from 
neoplastic multipotent myxoma cells (22). During the embryonic development, the foregut, and the 
primitive heart tube lie adjacent and the same area as most cardiac myxomas, i.e. foramen ovale, 
therefore glandular foregut rests might result to be embedded within myxoma, althongh embryonic 
glandula structures have never been described in the atrium septum so far.   
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Genetics  
The chromosomal patterns of sporadic cardiac myxoma are characterised by extensive intratumour 
heterogeneity. In the cases published to date, multiple unspecific chromosome aberrations have 
been reported, including dicentric chromosomes and, in particular, telomeric associations. 
Intratumour heterogeneity, as found in a variety of tumour types and grades, is considered a sign of 
genetic instability presumably resulting from disruption of genes that control genomic integrity. 
Studies of cardiac myxomas suggest that the chromosomal regions 12p1 and 17p1 may play a 
specific role in the development of these neoplasms since they are frequently rearranged.  
Whether there is a common genetic mechanism underlying sporadic and familial cardiac myxomas 
is unclear. Based on linkage analysis, 2 loci have been proposed for genes causally related to the 
myxoma syndrome: 2p16 and 17q2. A gene located at 17q24 was cloned that showed mutations in 
myxoma patients. This gene, PRKAR1A, represents a putative tumour suppressor gene, coding for 
the type 1 alpha regulatory subunit of protein kinase A, found in Carney syndrome. Neither 
mutations of PRKAR1A nor loss of heterozygosity of markers at 17q2 and 2p16 have been found in 
sporadic cardiac myxomas (54,55). 
Flow cytometry shows abnormally high tetraploid DNA patterns in all cases of syndromic 
myxomas, whereas in sporadic myxomas it is present only in about 20%.  
 
Genetic susceptibility  
Although most myxomas are sporadic, some have been associated with the myxoma complex. This 
autosomal dominat syndrome has been reported under the acronyms NAME (nevi, atrial myxoma, 
myxoid neurofibroma, ephelides), LAMB (lentigines, atrial myxoma, mucocutaneous myxomas, 
blue nevi), and more recently as Carney syndrome (14-18). This syndrome includes cardiac 
myxomas and extracardiac manifestations: abnormal skin pigmentation (lentigines and blue nevi), 
calcifying Sertoli-Leydig testicular tumours, cutaneous myxomas, myxoid breast fibroadenomas, 
pigmented adrenal cortical hyperplasia, pituitary hyperactivity, psammomatous melanotic 
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schwannoma and thyroid tumours. Familial myxomas are estimated to account for 7% of atrial 
myxomas, are more often multiple, recurrent and right sided, as compared to sporadic myxomas. 
The affected patients are also younger, most presenting at 20-30 years of age.  
 
Differential Diagnosis and Peculiar Clinical Aspects 
Differential diagnosis of intracardiac myxoid masses requires hystology.  Myxoid tumors of the 
heart may correspond to biologically benign myxoma, to myxoid sarcomas, or even to cardiac 
metastasis (56-58). The presence of myxoid stroma is not a pathognomonic feature and diagnosis of 
myxoma requires the presence of lepidic cells and the absence of mitosis. Hemorrhage, hemosiderin 
deposits, and inflammatory cells are frequently found in myxomas but are not specific (Figure 6.2). 
Base infiltration may be microscopically observed in myxomas, whereas in sarcomas and malignant 
tumors it is often quite extensive and grossly evident (6-9).  Few report have raised to controversial 
issue whether malignant variants of cardiac myxomas with metastatic potential do exist (23). The 
metastatic potential of cardiac myxoma might rather correspond to clinical consequences of tumor 
embolism and depend upon morphology of tumor, soft consistency, thrombotic depositions on the 
tumor surface and hemodynamic forces that may cause detachment of even conspicuous tumor 
fragments with embololism and even occlusion of pheripheral arteries causing ischemic damage of 
organs or tissue (19,20,22). Cardiac myxomas do not show a correspondent malignant countepart, 
and myxosarcoma is not a recognized entity in the present WHO classification of cardiac tumors 
(2). 
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Figure 6.2 A 20-year-old patient with a small left ventricular apical mass. (a) Two-
dimensional echocardiography, apical four-chamber view shows a round mass at the left 
ventricular apex (arrow) (LA left atrium, LV left ventricle, RA right atrium, RV right 
ventricle). (b) Gross view of the surgically resected mass: note the smooth surface and the 
pink color. (c, d) At histology and immunohistochemistry, the benign proliferation shows a 
myxoid background with vessel proliferation in keeping with myxomatous angioma 
(hematoxylin–eosin and CD31. From Basso et al., Circulation, 1998. 
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6.2  Papillary Fibroelastoma (or Papilloma) 
 
Definition: An endocardial based papilloma lined by endothelial cells with proteoglycan and elastin 
rich avascular stroma. 
Papillary fibroelastoma (PFE, also know as endocardial fibroelastic papilloma or giant Lambl 
excrescence) represents the second most frequent benign lesion after cardiac myxoma, excluding 
pericardial cyst (1,2,6,46,49,50,52). While in the past it was mostly an incidental autoptic 
obsevation, an exponential increase of clinically diagnosed PFEs occured in the last 20 years due to 
the wide-spread use of two-dimensional trans-thoracic and trans-esophageal ecocardiography, even 
in asyntomatic patients (59).  The true incidence is difficult to determine, as the tumour may be 
overlooked and there is morphologic overlap with Lambl excresences, a reactive age-related 
valvular lesion. In recent series of surgically excised cardiac tumours papillary fibroelastoma 
represents the second most frequent benign lesion (6,59).  
Papillary fibroelastoma is the second primary cardiac tumour following myxoma in Padua series 
(8%) (1,6) and it is the most common primary heart valve tumour (60-62) (Figure 6.3). It is 
predominant in the 4th and 5th decades of life and in males (63). 
 
Localization  
Gowda et al. reviewed 725 cases of cardiac papillary fibroelastoma reported in the literature, and 
found that the valvular endocardium was its predominant location (63). More than 95% arise in the 
left heart, including aortic (29%), mitral valve leaflets, mitral chordae and papillary muscles (25%). 
Unusual locations include the tricuspid (17%) and pulmonary valves (13%),, but also the mural 
non-valvular endocardium may be the site of growth, in the latter case being difficult to differentiate 
from thrombus and myxoma (60-66).  On gross examination, it is a small intra-cavitary neoplasm 
usually single, firm, with a short pedicle and multiple papillary fronds similar to a sea anemone 
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when under water (1,6).  This tumors are found most commonly (69.5%) on diseased valves, 37.8% 
post-rheumatic valves and 62.2% valves with fibrosis and calcification. Papillary fibroelastomas 
have been likened to Lambl excrescence, but unlike Lambl excrescences, which occur at the line of 
closure of semilunar valves, papillary fibroelastomas occur anywhere on the valve surface (67).  
Left-sided lesions are much more frequently symptomatic (2).  
 
Figure 6.3 Papillary fibroelastoma of the mitral valve in a 74-year-old woman who underwent 
coronary artery bypass surgery. (a) Trans-oesophageal 2D echocardiography: a round mass, 5 mm 
in diameter, is visible on the atrial side of the anterior mitral valve lea flet (AO aorta, LA left 
atrium, LV left ventricle, LVOT left ventricular out flow tract, RV right ventricle). (b) Gross view of 
the resected mass, showing the irregular surface with variable color. (c) At histology,a fibrin 
network is visible within the fibroelastic fronds of the tumor (Heidenhain trichrome stain). From 
Basso et al., Heart, 2003.  
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Macroscopy and histopathology 
Papillary fibroelastomas range in size from 2-50 mm in greatest dimension, although the majority is 
less than 10 mm. They are generally opalescent white, but this colour may be obscured by 
thrombus. They are usually attached to the endocardial surface by a short single stalk, but those 
with more than one attachment to the endocardium have been observed. Papillary fibroelastomas 
have multiple papillary fronds and, particularly when immersed in water, they resemble a sea 
anemone. Papillary fibroelastomas most often occur singly (80-90%). 
At histopathology, it is a papillary lesion with a thin layer of mucopolysaccharide matrix and 
avascular stroma composed predominantly of elastic fibres and a small amount of collagen, covered 
with a single layer of endothelial cells (65).  
Recent or organised thrombi may be observed, entrapped within the fronds, having the potential to 
lead to thrombo-embolic events. 
Surface endothelial cells express vimentin, CD34, CD31 and factor VIII related antigen (68).  
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6.3  Hemangioma 
 
Definition  
Haemangiomas are benign tumours composed predominantly of blood vessels. The histologic 
classification includes those composed of multiple dilated thin-walled vessels (cavernous type), 
smaller vessels resembling capillaries (capillary type), and dysplastic malformed arteries and veins 
(arterio-venous haemangioma, cirsoid aneurysm).  
Haemangioma accounts for approximately 1 to 5% of all benign cardiac tumours in different series 
(1,2,69-73). It occurs mostly in adults, and the clinical presentation varies depending on the location 
and size of the tumour. A total of 75% present with an intramural growth and 25% are sessile or 
polypoid, projecting into the atrial or ventricular cavities, sometimes mimicking myxoma. 
Epicardial location is also reported. Coronary angiography may be useful in detecting the distribu- 
tion of the afferent vessels to the tumour (Figure 6.4) (74). The histologic appearance is that of a 
proliferation of blood vessels lined by endothelial cells, which may be small capillaries (capillary 
haemangioma), large thin walled vessels (cavernous haemangioma, the most common type) or 
dysplastic malformation of arteries and veins (arteriovenous haemangioma or cirsoid aneurysm). 
Mixed forms are frequent. The prognosis of these tumours is unpredictable; they may even resolve 
(72,73), stop growing, or proliferate indefinitely. There is always the risk of recurrence, especially 
if there has been incomplete resection at initial surgery.  
 
Localization  
The most frequent locations are the lateral wall of the left ventricle (21%), the anterior wall of the 
right ventricle (21%), the interventricular septum (17%) and occasionally, the right ventricular 
outflow tract.  
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Figure 6.4 Right atrial hemangioma in a 62-year-old woman with effort dyspnea. (a) Trans-
oesophageal 2D echocardiography showing an atrial septal mass protruding into the atrial cavity 
to interfere with the blood flow: Color Doppler reveals an afferent coronary artery branch. (b) 
Selective coronary angiography confirms that the mass is vascularized from a collateral branch of 
the right coronary artery. (c) At histology, the mass consists of numerous vascular structures full of 
blood and lined by a single layer of endothelial cells (Heidenhain trichrome stain). (d) At 
immunohistochemistry, the lining cells are positive for endothelial markers (CD31). From Rizzoli 
G, et al., J Thorac Cardiovasc Surg., 2004.  
 
 
 
Macroscopy and histopathology 
The tumours are often large and gross appearance depends on the size of the vascular spaces in the 
tumour. The capillary type is frequently slightly raised from the endocardial sruface and appears red 
to purple. Intramuscular types will appear infiltrative. Cavernous haemangiomas are usually large 
and are also poorly circumscribed. Capillary haemangiomas are composed of nodules of small 
capillary-size vessels, each of which is subserved by a “feeder” vessel. This lobular or grouped 
  62 
arrangement of vessels is helpful for distinguishing these benign from malignant vascular 
proliferations. Mast cells and factor XIII-positive interstitial cells are a consistent feature. 
Intramuscular cardiac haemangioma has superficial resemblance to arteriovenous malformation, 
with the presence of heterogeneous vessel types, including muscularized arteries, veins, and 
capillaries. In contrast to capillary haemangioma, they are infiltrative lesions and occur within the 
myocardium.  
Cavernous haemangiomas are composed of large dilated vascular spaces. They tend to infiltrate the 
myocardium. The lining cells are bland and flattened and mitotically inactive.  
 
Genetic susceptibility  
Genetic susceptibility to cardiac haemangiomas has not been identified. Extracardiac 
haemangiomas occur in a variety of contexts. They may be single sporadic lesions or multiple 
lesions that are components of complex genetic syndromes. Capillary haemangiomas occur in up to 
10% of live births and are the most frequent tumour in newborns. When these tumours occur in the 
absence of associated syndromes, they may represent manifestations of an autosomal dominant 
mendelian trait. Linkage analyses of multiplex kindreds affected by hereditary capillary 
haemangiomas have identified loci on chromosome 5 (q31- q33 and q13-q22) that appear to contain 
as yet unidentified causal disease genes.  
A wide array of complex syndromes, such as von Hippel Lindau syndrome and phocomelia/ 
Roberts syndrome, that can be transmitted in a mendelian fashion include haemangiomas as 
components of their clinical presentations. The Klippel-Trenaunay-Weber syndrome, in which 
cutaneous haemangiomas occur in the setting of osseous hypertrophy, shows familial clustering, but 
a clear mode of inheritance has not been established. Autosomal paradominant and dominant modes 
of inheritance have been proposed. Translocationshave been identified in 2 Klippel-Trenaunay-
Weber patients, t(5;11) (q13.3;p15.1) and t(8;14)(q22.3; q13), but specific gene defects remain to be 
identified (2).  
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Somatic genetics  
Specific genes have been associated with two disorders involving arteriovenous malformations. 
Mutations in the gene on chromosome 9p21 encoding the endothelial cell-specific receptor tyrosine 
kinase TIE2 cause the autosomal dominant Bean or “Blue rubber-bleb nevus” syndrome and 
familial multiple cutaneous and mucosal venous malformations. At least some cases of hereditary 
cerebral cavernous malformations are caused by mutations in the chromosome 7q21-q22 Krev 
interaction trapped-1, KRIT-1, gene KRIT1 normal binds to RAP1A, a Ras GTPase, and the disease 
causing mutations appear to disrupt these interactions. Other genetic loci for this disorder have been 
identified at chromosomes 17p15- p13 and 3q25.2-q27 and remain to be studied. The genetic and 
clinical relationship of this disorder to hereditary neurocutaneous angioma is unclear.  
 
Syndromic associations  
The majority of cardiac haemangiomas are sporadic and isolated, without evidence of extracardiac 
vascular lesions. Rarely, there may be extracardiac haemangiomas of the gastrointestinal tract and 
port-wine stain of the face. Giant cardiac haemangiomas can result in thrombosis and 
coagulopathies (Kasabach-Merritt syndrome) (2).  
 
 
 
 
6.4 Lipoma  
 
Definition: Benign tumour composed of mature, white adipocytes.  
Lipoma was first described by Orth in 1886. It is a benign tumour made up of mature fat cells, 
reported at any age with equal frequency in both genders, with an incidence of 8% (1,2,75,76).  
The true lipoma, which are single or multiple capsulated fatty masses, yellow, soft, and originating 
from the endocardium, epicardium or myocardium, should be kept distinct from so-called 
lipomatous hypertrophy of the interatrial septum. The latter, which should not be considered proper 
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by a tumour, is a non encapsulated adipose tissue mass, probably an intracardiac extension of the 
sub-epicardial fat of the right atrioventricular sulcus, usually observed in obese, old people (Figure 
6.5) (77,78).  
 
Figure 6.5 Lipomatous hypertrophy of the atrial septum (atrial septal lipoma) at autopsy in a 74 
year-old woman with a history of tuberculosis and diabetes (a) Ex vivo cardiac magnetic resonance 
showing a hyperintense signal similar to that of epicardial fat. (b) After longitudinal section of the 
heart, an oval-shaped lipomatous mass, 3x2 cm in size, is visible in the atrial septum. (c) At 
histology, the non-capsulated mass presents mature adipocytes with tiny interstitial fibrosis and 
rare cardiac myocytes (Heidenhain trichrome stain). (d) Close-up of C (Heidenhain trichrome 
stain). From Basso et al., Circulation, 1998. 
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Localization  
Cardiac lipomas may occur anywhere in the heart. There is a predilection for the pericardium and 
epicardial surfaces where they may attain enormous sizes. Other sites include the ventricular septum 
and cardiac valves. When they involve the latter site, the designation “fibrolipoma” has been used. 
 
Histopathology  
Similar to extracardiac lipomas, cardiac lipomas are circumscribed masses of mature adipocytes in a 
fine fibrovascular network, at difference from lipomatous hypertrophy which shows myocardial 
tissue with wide-spread infiltration of fat-cells (77,78).  
 
Differential diagnosis  
The main differential diagnosis is lipomatous hypertrophy, a non-encapsulated lesion composed of 
mature fat and adipocytes resembling brown fat cells intermixed with enlarged cardiac myocytes 
occurring solely in the interatrial septum. Lipomatous hypertrophy is most often an incidental 
finding at autopsy, but may uncommonly be the cause of unexplained atrial arrhythmias, AV Block, 
congestive heart failure, or superior vena cava obstruction.  
The differential diagnosis also includes the intramuscular variant of haemangioma, which may 
contain variable numbers of adipocytes.  
 
6.5 Fibroma  
 
Fibroma is a rare primary heart tumour composed of fibroblasts or myofibroblasts with a matrix 
containing collagen. It almost exclusively occurs within the myocardium of the ventricles or 
ventricular septum. It is not clear whether it is a hamartoma or a true neoplasm. Because most cases 
occur in infants and children it is likely congenital. Fibroma is the second most common tumour in 
the paediatric population after rhabdomyoma (79-86). It represents nearly 20% of paediatric cardiac 
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tumours in Padua experience (1,6, 82,83). 
Localization  
Most fibromas are solitary, well circumscribed, firm, located within the left ventricular free wall or 
interventricular septum, thus producing compression of the conduction system, reentry ventricular 
arrhythmias or obstruction of the ventricular lumen (79,86). Atrial fibromas are quite rare. 
 
Macroscopy and histopathology 
They are typically rounded masses that are fibrous, white and whorled.  They are nearly always 
mural although polypoid endocardial based lesions have been reported. Most occur singly. The 
mean diameter is 5 cm. Fibromas are composed of bland-looking spindle cells forming loose 
intersecting bundles. They are not encapsulated and extend into the surrounding myocardium. Even 
in grossly circumscribed cases, entrapped myocytes can often be seen deep within the tumours, far 
from the gross margins. The fibroma cells have oval or tapered nuclei without nucleoli. Their 
cytoplasm is pale. These cells are associated with abundant collagenous stroma, which increases 
with the age of the patient. Tumour cells express vimentin and smooth muscle actin, both in cellular 
and fibrous lesions. Cellular lesions are observed in infants during their first months of life, while 
fibromas in older patients contain large amounts of collagen. Mitoses and foci of extramedullary 
haematopoiesis may be present in cellular tumours. Calcification is observed in lesions from 
patients of all ages, more common in older individuals. Wavy elastic fibers are frequent and may be 
prominent. Focal myxoid change in the stroma and chronic inflammation may also be present.  
Prognosis and predictive factors  
The cardiac fibroma is benign, but its nature of slow but continuous growth may cause conduction 
defects, arrhythmias with even sudden death. Extension into the ventricular free walls may result in 
atrioventricular valve inflow or arterial outflow obstruction. Spontaneous regression as can occur 
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with congenital rhabdomyoma has not been observed (Figure 6.6). 
 
Figure 6.6 A 40-year-old woman, with echocardiographic diagnosis of asymmetric hypertrophic 
cardiomyopathy, underwent cardiac transplantation due to refractorycongestive heart failure (a) 
Long axis section of the native heart showing a huge oval shape whitish mass occupying the 
interventricular septum and accounting for subaortic bulging/obstruction. (b) At histology, a 
cardiac fibroma was diagnosed (Heidenhain trichrome). From Valente et al., J Thorac Cardiovasc 
Surg, 1993. 
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6.6 Cystic tumour of the atrioventricular (AV) node  
 
The cystic tumour of the atrioventricular (AV) node, first described in 1911, involves the 
atrioventricular node selectively. It is also known as tawarioma ( Figure 6.7)(from Tawara, who 
discovered the AV node) or celothelioma (mesothelioma of the AV node) reflecting its 
controversial histogenesis (87-91). The mean age of clinical presentation is nearly 40 years. The 
75% of patients present with complete and 15% with incomplete AV block, whereas in 10% sudden 
death is the first clinical manifestation (92). On a large scale, the tumour appears multicystic, with 
size varying from 2 to 20 mm. Histologically, the tumour is located on the right side of the central 
fibrous body, infiltrating and compressing the AV node. The cysts are filled by a mucoid substance 
and are lined by epithelium, cytokeratin and epithelial membrane antigen positive (93). Diagnosis is 
usually achieved at post-mortem or after cardiac transplantation (94) through histological 
examination of the conduction system, but occasionally in vivo or during surgical resections.  
Figure 6.7 Cystic tumor of the AV node, incidental finding at autopsy in a 78-year-old woman who 
died of ischemic heart disease. Histologic section at the level of the AV node: note the 
subendocardial mass consisting of multiple cysts variable in size fi lled with mucoid material 
(Alcian PAS). (b) The cysts are lined by cuboid and transitional cells (hematoxylin–eosin stain. 
From Basso et al., Cardiac Tumor Pathology, 2013. 
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6.7 Intracardiac blood cyst  
 
Intracardiac blood cysts are rare, usually small and asymptomatic lesions, located in the 
endocardium most frequently along the closure rim of the atrio-ventricular valves in newborns and 
infants, particularly under 2 months of age, due to blood entrapped in the leaflet. The cysts are 
single blood-filled spaces lined by a layer of endothelial cells. They may regress spontaneously, 
thus are rare in adults. Occasionally, the blood sequestration may increase and the cyst assumes a 
huge endocavitary dimension, creates obstructive symptoms and requires surgery (95,96).  
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CHAPTER 7 
OTHER CONGENITAL AND CHILDHOOD TUMORS 
 
7.1 Histiocytoid Cardiomyopathy  
 
Histiocytoid cardiomyopathy has in the past been designated oncocytic cardiomyopathy, Purkinje 
cell hamartoma, or cardiac hamartoma. It is a multifocal hamartomatous collection of cells that 
resemble modified myocytes of the conduction system (1). Histiocytoid cardiomyopathy is rare, 
with fewer than 150 reported instances (2) (Figure 7.1). Most affected patients are infants in the 
first year of life who have ventricular tachyarrhythmias or die suddenly. More than one-third of 
children have additional anomalies, both cardiac and extracardiac. Recently, a novel mutation in the 
NADH:ubiquinone oxidoreductase subunit B11gene (NDUFB11) has been identified in a few 
probands by direct sequencing, suggesting a role in the pathogenesis of the disease (3). There have 
been sporadic reports of mutations in mitochondrial genes; only a few cases (5%) are familial (4).  
Grossly, the tumors present as endocardial or myocardial nodules and may also involve the 
sinoatrial and atrioventricular nodes. Histologically, the cells are finely vacuolated, rounded 
myocytes that ultrastructurally demonstrate numerous mitochondria and disordered myofibrils.  
Figure 7.1 Histiocytoid cardiomyopathy. A serial histological sections study of the specialized 
conducting tissue reveals foci of histiocytoid cells (asterisks) in the His bundle (HB) and left bundle 
branch (LBB) as well as adjacent myocardium. From Rizzo et al., Heart Rhythm, 2014. 
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7.2 Rhabdomyoma  
 
Rhabdomyoma is considered the most common paediatric cardiac neoplasm, accounting for 90% of 
primary benign tumours in this age group (5-8). Nevertheless, in Padua surgical paediatric 
experience (9), only 15% of paediatric cardiac tumours were rhabdomyoma, since usually there is 
no indication for surgery because of spontaneous regression of the neoplasm along the natural 
history. Rhabdomyomas are single or, more frequently, multiple non-capsulated nodules, white or 
grey, up to 1–2 cm in diameter, usually intramural within the ventricular myocardium, but also 
intracavitary because of growth from the sub-endocardium (Figure 7.2). 
Rhabdomyomas are firm, white, well-circumscribed single or multiple lobulated nodules that occur 
in any location of the heart, but are more common in the ventricles (Figure 7.3). In patients with 
tuberous sclerosis, tumours are usually multiple (<90%) and can consist of numerous miliary 
nodules measuring less than 1 mm; in this instance, the term “rhabdomyomatosis” has been used 
and consisting of a classical clinical triad, i.e. neurofibromatous lesions, mental slowing and 
cutaneous lesions and due to mutation of genes coding for two tumour suppressors, amartin (9q34) 
and tuberin (16p 13.3). The most common locations are the left ventricle and ventricular septum, 
although 30% will have atrial wall or right ventricular involvement . In contrast to patients with 
tuberous sclerosis, approximately 50% of sporadic rhabdomyomas occur singly.  
Single or multiple, they are well-circumscribed, non-capsulated white or grey white nodules which 
may vary in size from millimeters to several centimeters. Tumours can become quite large, espe- 
cially in sporadic cases. They most often occur in the ventricle, but can be found in the atria, at the 
cavoatrial junction and on the epicardial surface. Large tumours may obliterate and distort a 
ventricular cavity.  
Cardiac rhabdomyomas consist of large, vacuolated, clear myocytes full of glycogen, with residual 
cytoplasm stretching from the central nucleus to the membrane, giving rise to a spider appearance 
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(“spider cells”). More than a proliferation of cardiomyocytes, the rhabdomyoma is a localised 
storage disease of glycogen, which may account for severe contractile ventricular dysfunction. The 
majority of cells show vacuolization with sparse myofilaments. There is a strong reaction with 
periodic acid-Schiff reagent, reflecting the presence of abundant intracellular glycogen (Figure 7.2) 
(10,11).  
 
Figure 7.2 Rhabdomyoma in a 7-month-old child with subaortic stenosis. A Two-dimensional 
echocardiography showing the left ventricular outflow obstruction due to an endocavitary mass 
attached to the anterolateral wall in the subaortic area. B At histology, patognomonic spider cells 
with cytoplasmatic myofibrils radiating to the cell periphery (hematoxylin-eosin stain). From De 
Dominicis et al, Chest. 1989;95:470–2.  
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Immunohistochemical studies document the striated muscle characteristics of rhabdomyoma cells, 
which express myoglobin, desmin, actin, and vimentin. Tumour cells do not express cell prolifer- 
ation markers such as Ki-67 and PCNA, indicating that the lesions are more likely hamartomas as 
opposed to neoplasms. The diagnosis of cardiac rhabdomyoma in infants and young children is 
straight-forward. Differently in the adult cellular rhabdomyoma there are striated myocytes and it is 
frequently similar to tumour of the head and the neck region (extracardiac rhabdomyoma). In 
contrast to congenital rhabdomyomas, adult cellular rhabdomyomas occur in adults, demonstrate 
evidence of cellular proliferation e.g. by expression of Ki-67 antigen, and contain relatively few 
vacuolated or spider cells. Unlike hamartoma of mature cardiac myocytes, the tumours are well 
circumscribed, and although not as frequent as in congential rhabdomyoma, some vacuolated cells 
are usually present. Furthermore, the disorganized masses of myofilaments characteristic of 
hamartoma of mature cardiac myocytes are not seen. Rhabdomyosarcoma shares some features with 
adult cellular rhabdomyoma. Despite the evidence of cell proliferation in the latter tumours, the 
absence of tumour necrosis, mitotic figures, myogenin expression, and the presence of a well-
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defined pseudocapsule help to distinguish it from rhabdomyosarcoma. The prognosis of adult 
cellular rhabdomyoma is unknown, but presumed to be benign, based on the biologic behaviour of 
extracardiac rhabdomyomas in adults. Late recurrences have been described in extracardiac 
rhabdomyoma (1). 
Figure 7.2 CMR and histology features of intramural left ventricular mass. (A) ECG-triggered 
breath-hold proton density T1-weighted fast spin echo in coronal plane, showing a large 
homogeneous isointense mass involving the left ventricular wall; (B) ECG-triggered breath-hold 
cine steady-state free procession in axial plane, showing the cardiac mass involving the 
interventricular septum; (C) ECG-triggered breath-hold cine steady-state free procession in four-
chamber view, showing no intracardiac obstruction; (D) Histopathology study shows enlarged 
swollen myocytes with clear cytoplasm and centrally located nucleus, connected with the periphery 
of the cell by strands of cytoplasm (spider cells); (E) the enlarged cells are vacuolated due to the 
abundant glycogen deposits in the cytoplasm; immunohistochemistry (inset) reveals striated 
muscular cell (spider cell) staining positive for myosin in keeping with cardiac rhabdomyoma. Ao, 
aorta; LA, left atrium; LV, left ventricle; RA, right atrium; RV, right ventricle. From Padalino et 
al., Circulation, 2011 
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7.3 Rare Hamartomas  
 
 “Hamartoma of mature cardiac myocytes,” is composed entirely of heart muscle cells. Its 
distinction from rhabdomyoma is that the cells appear mature without the vacuolization seen in 
rhabdomyoma.  
Unlike rhabdomyoma, hamartomas of mature cardiac myocytes occur in adults. Histologically, they 
resemble areas of myofiber disarray as seen in hypertrophic cardiomyopathy but are circumscribed 
masses. 
Other rare hamartomatous tumors in the heart contain areas of mature fat as a component of the 
lesion. These include hamartoma of cardiac valves  which have a mixture of fat and fibrous tissue, 
and rare intramuscular cardiac tumors with fat, vessels, heart muscle cells, and nerves. Because this 
so-called mesenchymal hamartoma has been reported only once and overlaps significantly with 
intramuscular hemangiomas (except for the nerve tissue), it is not considered a separate entity in the 
WHO classification of heart tumors (1).  
 
7.4 Germ Cell Tumors (Teratoma and Yolk Sac Tumor)  
 
Germ cells tumors are classified depending on the germ they derive from, such as seminoma (or 
dysgerminoma), embrional carcinoma, yolk sac tumor, choriocarcinoma, and teratoma (12). 
Diagnosis occurs typically within the first month of life (13,14). They are very rare, usually benign, 
in contrast with those occurring in adult age which are mostly malignant germ cell tumors. This is 
solitary, encapsulated cystic masses with intervening solid areas, often connected to the aortic root 
or to the pulmonary artery by means of a thin vascularized pedicle. They are usually localized at the 
base of the heart, anterior to the aorta, close to the superior vena cava, and may cause compression 
of these latter structures but also of the right atrium, atrial septum and ventricle and of the 
pulmonary artery (15). The neonate with an intrapericardial teratoma is usually severely 
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symptomatic Pericardial effusion is commonly associated. This may concur in causing a severe 
respiratory distress, cardiac tamponade, and low cardiac output syndrome that may be fatal if 
prompt diagnosis and treat- ment are not provided (16,17). Diagnosis is usually achieved with two-
dimensional echocardiography during both the fetal and the neonatal period (15,16).  
Surgical resection of the mass is often lifesaving (18). 
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CHAPTER 8 
 
PRIMARY MALIGNANT CARDIAC TUMOURS 
 
Primary malignant cardiac tumours are very rare, representing nearly 10% of all primary cardiac 
neoplasms (1,2). Sarcomas represent 95% of these tumours (about 10% of all primary cardiac 
tumours, angiosarcomas and unclassified sarcomas being the most common accounting for 76%), 
and primary lymphomas and mesotheliomas make up the remaining 5% (3-11). All varieties of soft 
tissue sarcomas have been reported to arise in the heart. Primary cardiac sarcomas can occur at any 
age, but are more frequently diagnosed between the third and fifth decades, and equally in men and 
women (2), whereas they are extremely rare in the paediatric age group. Surgical excision is the 
most effective treatment for primary cardiac malignancies. However, prognosis is very poor in spite 
of additional treatments, such as radiotherapy and chemotherapy, with a median survival of less 
than one year and 80% of patients already present diffuse infiltration of the heart and metastases at 
the time of diagnosis (8-12). A less-aggressive course seems related to the left atrium location, a 
low histologic grading with scarce cellular pleomorphism and low-mitotic activity, absence of 
necrosis, and absence of metastasis at diagnosis.  
 
8.1 Angiosarcoma  
 
Angiosarcoma is the most common primary malignant cardiac tumour, with a peak in the 4th 
decade and no sex predilection (1,2,12). The most frequent location is the right atrial chamber. The 
presenting signs and symptoms are non-specific and may include right sided heart failure, 
symptoms of pericardial involvement or vena cava obstruction. Echocardiography usually 
demonstrates a broad based right atrial mass near the inferior vena cava and AV sulcus. On CT and 
MRI they show arterial phase enhancement permitting a definitive diagnosis.  
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Figure 8.1 Angiosarcoma in 36- year-old woman, suffering from dyspnea and fever  (a) Two-
dimensional echocardiogram, apical four-chamber view, showing an irregular, both endocavitary 
and intramural large mass (arrows) in the right atrium (RA), extending into the right ventricle 
(RV), 6x8cm in size. ( b ) Histology of the transvenous endomyocardial biopsy of the mass: the 
myocardium appears infiltrated by pleomorphic spindle cells with hyperchromatic nuclei forming 
vascular channels (hematoxylin–eosin stain). (c) Immunostaining against myoglobin is strongly 
positive in the normal myocardium but not in the neoplastic proliferation. (d) The tumor cells 
arranged in vascular channels are positive to factor VIII (LV left ventricle) 
From Poletti et al., Cardiovasc Pathol., 1993. 
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Pulmonary metastases are frequent, and survival after diagnosis rarely exceeds 6 months. On a large 
scale, it is an intramural neoplasm, brownish and lobulated, infiltrating the wall and the 
pericardium, and protruding into right cardiac cavities, with invasion of the inferior vena cava and 
the tricuspid orifice. The site is ideal for in vivo diagnosis through endomyocardial biopsy (13). At 
histology, two thirds of angiosarcoma are well to moderately differentiated and show an irregular, 
anastomosing, vascular network, lined by pleomorphic, atypical cells with frequent mitoses. In one 
third of cases, the tumour is poorly differentiated, consisting of anaplastic spindle cells within a 
hyaline stroma, containing focally extravascular red cells. Immunohistochemistry plays a crucial 
role in diagnosis, confirming the endothelial nature of malignant cells, strongly positive with factor 
VIII, CD31 and CD34 (Figure 8.1).  
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8.2 Malignant pleomorphic fibrous histiocytoma (MFH)/undifferentiated pleomorphic 
sarcoma 
Malignant pleomorphic fibrous histiocytoma (MFH)/undifferentiated pleomorphic sarcoma 
accounts for one-third of all cardiac sarcomas and have been incorporated in the malignant fibrous 
histiocytoma/pleomorphic sarcoma subgroup (1,2).  
 
Figure 8.2 Left atrial malignant fibrous histiocytoma in a 68 -year-old man, presenting with fever 
and increased serum in fl ammatory markers. (a) Two-dimensionalechocardiography: an 
endoluminal round mass is visible in the left atrium, simulating a myxoma. (b) Grossly, the surgical 
resected mass showed a rough and irregular surface. (c) At histology, bizarre cells with 
pleomorphic nuclei admixed to giant cells and spindle-shaped cells, with high mitotic rate are seen 
(hematoxylin–eosin stain). (d) At immunohistochemistry, the tumor cells are positive to vimentin. 
From Basso et al., Cardiac Tumor Pathology, 2013. 
 
 
  
  92 
This is an exclusion diagnosis, when all the immunohistochemical stains fail to give evidence of 
specific differentiation. Once, when immunohistochemistry was not available, undifferentiated 
sarcoma represented 50% of all cardiac malignancies, but in more recently published series it has 
almost disappeared. Most frequently it arises in the left atrium, with an endocavitary growth, 
mimicking left atrial myxoma at echocardiographic examination. Differential diagnosis should also 
consider intracavitary thrombi. Macroscopically, the mass is clearly distinguishable from myxoma 
because it may be multiple, whitish with a rough surface and hard consistency, in the absence of 
gelatinous appearance. Microscopically, it consists of pleomorphic cells, frequently giant 
multinuclear, with high mitotic activity and positivity only for vimentin at immunostaining (Figure 
8.2). 
 
8.3 Leiomyosarcoma  
 
Leiomyosarcoma is a primary sarcoma of smooth muscle cells and accounts for nearly 10% of all 
cardiac malignancies, with a peak in the 5th decade and no sex prevalence (1,2,14,15).  
There are two usual sites of origin. One is the left atrium, where it may present as a single or 
multiple endocavitary mass, mimicking the left atrial myxoma although usually attached to the 
atrial roof rather than the atrial septum (14); the second, is the pulmonary infundibulum and artery, 
mimicking pulmonary embolism (15). On a large scale, the mass is irregular, solid, and whitish or 
grey. Histologically, fascicles of spindle cells, smooth muscle actin and desmin positive, with blunt-
ended nuclei, oriented at right angle with mitoses are visible. Pleomorphism, giant cells and 
necrosis are focally present (Figure 8.3).  
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Figure 8.3 Left atrial endocavitary mass. (A and B) Two-dimensional echocardiography, 
parasternal long-axis view (systole and diastole): note the tumour prolapse during diastole and the 
mass attached to the roof of the left atrium; (C) Gross examination of the surgically resected mass: 
note the firm, homogeneous and whitish appearance; (D) Histology shows pleomorphic cells 
arranged in a storiform pattern with a myxoid background; the cells are staining positively for 
desmin (inset), in keeping with a diagnosis of leiomyosarcoma. From Basso et al., Heart, 2016. 
 
 
 
 
8.4 Fibrosarcoma  
 
Fibrosarcoma consists of a malignant proliferation of mesenchymal cells with fibroblastic features 
and a storiform, herring-bone pattern with a collagen stroma (1,2,16) (Figure 8.4). They represent 
nearly 5% of all primary cardiac malignancies. The most frequent location is in the atria 
(particularly the left), with both intracavitary and mural location. A pericardial form does exist 
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(solitary malignant fibrous tumour of the pericardium), which may mimic a mesothelioma. As with 
other sarcomas, clinical presentation depends on the site and size of the tumour. Being mostly left 
sided, signs and symptoms of pulmonary congestion, mitral stenosis and pulmonary vein 
obstruction are the most frequent.  
Microscopically, the fibrosarcoma consists of a collagen stroma and monomorphic spindle cells, 
with variable mitotic index. Pleomorphism, giant cells and vascularisation are absent.  
Immunohistochemistry is positive for vimentin and frequently also for actin, in keeping with a 
myofibroblastic differentiation.  
The prognosis is poor (mean survival 5 months), even in intracavitary cases in which surgical 
resection is apparently radical.  
Myxoid fibrosarcoma is grouped among fibroblastic/ myofibroblastic neoplasms.  
 
Figure 8.4 Fibrosarcoma of the right atrium in a 62 -year-old woman, suffering from weakness and 
effort dyspnea. (a) CT showing a mass in fi ltrating the right atrial free wall. (b) Transvenous 
endomyocardial biopsy: panoramic view of bioptic specimens (hematoxylin–eosin stain). (c) At 
higher magni fi cation, note atypical spindle cells within a fi brous stroma (hematoxylin–eosin 
stain).(d) At immunohistochemistry, the tumor cells are positive for vimentin. From Basso et al., 
Cardiac Tumor Pathology, 2013. 
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8.5 Rhabdomyosarcoma  
 
Rhabdomyosarcoma is a rare malignant tumour of striated muscle, most frequently encountered in 
children with male prevalence (1,2,17) (Figure 8.5). Rhabdomyosarcomas arise de novo, not from 
malignant degeneration of a rhabdomyoma. It often diffusely infiltrates the myocardium at any 
location, presenting with cardiac obstructive phenomenon, arrhythmias or pericardial effusion.  
Embryonal rhabdomyosarcoma is the most frequent at cardiac level thus explaining the younger age 
at presentation. Within a rich proliferation of round cells with frequent mitoses, PAS positive 
rhabdomyoblasts are visible with the typical feature of “tadpole” and positive at 
immunohistochemistry for vimentin, muscle-specific actin, desmin and myogenin. Electron 
microscopy reveals cells containing contractile filaments with a “Z-band-like” appearance.  
 
Figure 8.5 Rhabdomyosarcoma in a 36- year-old patient at autopsy. (a) Chest X-ray shows 
pericardial and right pleural effusion. (b) At ECG, atrio-ventricular dissociation is present. (c) At 
autopsy, the tumor appears as a bulky mass in fi ltrating the left atrial posterior wall. (d) At 
histology, tumor cells appear pleomorphic and tadpole-like, with small transverse bands in the 
cytoplasm (hematoxylin–eosin stain. From Basso et al., Cardiac Tumor Pathology, 2013. 
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8.6 Liposarcoma  
 
Liposarcoma is a rare entity (1% of primary malignant tumours of the heart) (1,2) that 
predominantly appears as a bulky endocavitary left atrial mass, mimicking myxoma, with early 
signs of local invasion and haemodynamic disturbance.  
It looks like an intramural, sessile or pedunculated mass, gelatinous and un-encapsulated. 
Microscopically, it consists of lipoblasts, irregular cells, with large pleomorphic nuclei and 
cytoplasmatic fat vacuoles, S100 positive at immunohistochemistry.  
 
8.7 Cardiac lymphoma  
 
It represents 5% of primary cardiac malignant neoplasms, which means 1% of all cardiac primary 
tumours. It occurs in ages from 5 to 90 years (median 60), the male/female ratio is approximately 
3:1, and it does not necessarily occur in immune-deficient people. It ay arise in any cardiac 
chamber, but in 2/3 of cases the right atrium is the site of involvement with an intramural, whitish 
infiltrating mass extended to pericardium with massive effusion.  
Primary cardiac lymphoma is an extranodal non-Hodgkin’s lymphoma. The subtype most 
frequently observed (80% of cases) is B-cell lymphoma with huge, CD20 positive cells, whereas the 
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remaining 20% are CD3 positive T-cell lymphomas. Cytology of pericardial effusion may be of 
help for diagnosis, by using molecular techniques to differentiate B and T-cell lymphomas from 
reactive lymphocyte hyperplasia. Primary cardiac lymphomas should be promptly treated like 
aggressive lymphomas in other sites, since a late diagnosis is the major determinant of a poor 
prognosis. It is worthwhile to note that primary cardiac lymphomas, with chemo-therapy, are the 
only malignant cardiac neoplasms to present a fairly good prognosis (1,2)(Figure 8.6 ).  
 
 
Figure 8.6 Primary cardiac lymphoma in a 36- year-old man, drug abuser and HIV infected, with 
echocardiographic finding of a mass infiltrating the right atrial free wall. ( a ) The myocardium is 
diffusely infiltrated by proliferating neoplastic cells (hematoxylin–eosin stain).( b ) Border area 
between the neoplastic in filtration and normal myocardium (hematoxylin–eosin stain). ( c ) At 
higher magnification, the tumor cells are large with large nuclei (hematoxylin–eosin stain). ( d ) At 
immunohistohemistry, tumor cells are positive for CD20, a B-cell marker. From Basso et al., 
Cardiac Tumor Pathology, 2013. 
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8.8 Grading 
For many years, no universally accepted classification of primary cardiac sarcomas existed. The 
difficulty derived from the rarity of cardiac sarcomas reported in the literature. All soft tissue 
sarcoma types have also been found to arise in the heart. There is no grading system for malignant 
cardiac tumors and criteria for soft tissue neoplasms are used (18). As for soft tissue, cardiac 
sarcomas can be classified by biological and histologic aspects. 
First, in the new WHO classification of Soft Tissue Tumours it is recommended to divide soft tissue 
tumours into the following four categories: benign, intermediate (locally aggressive), intermediate 
(rarely metastasizing) and malignant (18). 
Second, histologic grading of malignancy of cardiac sarcomas has the greatest correlation with 
survival, with the important exception of angiosarcoma.   
Grading, based on histological parameters only, evaluates the degree of malignancy and mainly the 
probability of distant metastasis. Staging, based on both clinical and histological parameters, 
provides information on the extent of the tumour. The concept of grading in soft tissue tumors was 
first properly introduced by Russell et al in 1977 (19), and was the most important factor of their 
clinico-pathological classification. Several grading systems, based on various histological 
parameters, have been published and proved to correlate with prognosis (20-23). The main 
parameters in non-cardiac soft tissue tumors are the mitotic index and the extent of tumor necrosis 
(18,20).  Three grades of malignancy are usually identified: G1, low grade; G2, intermediate grade; 
G3, high grade. The French Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) 
classification is the grading system that seems to better correlate with survival of soft tissue 
sarcomas. The FNCLCC system is based on a score obtained by evaluating three features: tumor 
differentiation, mitotic rate, and amount of tumor necrosis. A score is attributed independently to 
each of the three parameters and the final histological grade is the sum of the three attributed scores 
(Table 8.1 ) (21). 
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Table 8.1 Parameters of the grading system for sarcomas of the Féderation Nationale des Centres 
de Lutte contre le Cancer (FNCLCC)  Modified from Trojani et al. Int J Cancer. 1984.  
a A hight-power field (HPF) measures 0.1734 mm2 
As a general rule, grading should be used only for untreated primary soft tissue sarcomas and 
should be performed on representative material (for instance, tissue obtained through endomyocar- 
dial biopsy cannot be used for grading purposes).  
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CHAPTER 9 
 
 
TUMOURS OF THE PERICARDIUM 
 
Primary pericardial tumours are rare, and include benign (cyst, teratoma, fibroma, angioma and 
lipoma) and malignant (mesothelioma and sarcoma) forms. More frequently, the pericardium is 
secondarily involved by direct extension, retrograde lymphangitic spread or hematogenous 
dissemination. The patients present with pericardial effusion and occasionally pericardial 
tamponade (1,2).  
 
9.1 Pericardial cyst  
A pericardial cyst is a relatively frequent mass, uni- or multiloculated, full of serous liquid, 
probably disontogenetic in origin, but symptomatic in adult age because of increasing storage of 
fluid within the cystic cavity. Histologically, the thin wall consists of highly vascularised 
connective tissue covered by mesothelium on both sides (3).  
9.2 Teratoma  
Teratoma is a tumour of germinal cells, which represents nearly 10% of all paediatric cardiac 
tumours. In 90% of cases it is located within the pericardial cavity, usually at the base of the heart. 
Diagnosis is usually achieved within one month of age because of severe obstructive symptoms by 
compression of the arterial pole. Pericardial effusion may occur and lead to cardiac tamponade. On 
a large scale, they appear as cystic lesions, clearly visible with clinical imaging. Histologically, 
proliferation of various tissues from two or three embryonic leaflets is visible (gastrointestinal, 
cartilagineous, bony, bronchial, nervous), easily identified by immunohistochemistry (3).  
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9.3 Malignant Mesothelioma  
Malignant mesothelioma is the most common primary malignancy of the pericardium. It accounts 
for only about 1% of all mesotheliomas. It affects individuals of any age (mean 45 years), with a 
male predominance. The role of asbestos in pericardial mesothelioma is unclear. A role for 
radiotherapy for mediastinal neoplasms and breast cancer has also been advocated (4). 
Mesothelioma arises from the mesothelium. It occurs most frequently as diffuse pericardial 
thickening, encasing the heart. The cells are large pleomorphic cells with abundant pale cytoplasm 
and well demarcated cell borders, positive for cytokeratin, vimentin, epithelial membrane antigen 
and calretinin and negative to carcinoembryonic antigen, the latter being instead positive in 
pericardial metastasis of adenocarcinoma. It is in fact imperative to rule out any neoplasm with 
secondary pericardial involvement (4).  
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CHAPTER 10 
 
METASTATIC TUMOURS TO THE HEART 
 
Definition  
The heart can be the target of metastases from any extracardiac malignant neoplasm able to spread 
to distant site. Metastatic tumours are malignant cardiac neoplasm that may be infiltrate the 
myocardium and may be frequently associated with pericardial metastases, especially in the cases of 
carcinomas, which additionally involve mediastinal lymph nodes.  
Epidemiology  
The incidence of secondary cardiac tumors at autopsy ranges from 1.7% to 14% (average, 7.1%) in 
cancer patients and from 0.7% to 3.5% (average, 2.3%) in the general population (1). In contrast to 
older series, a significant increase in the incidence of cardiac metastases in cancer patients was 
noted after 1970, predominately because of improvement in imaging modalities. An investigation 
performed at Padua University in the time interval 1967-1976 revealed that among 7,460 autopsies 
the cause of death was malignancies in 1,181 cases (15,33%), in 74 of which cardiac metastases 
occurred (2).   
Clinical features  
The cardiac location of the tumor greatly affects the signs and symptoms. These can include 
symptoms related pericardial effusions, arrhythmias, or congestive heart failure. Obstruction of the 
mitral or aortic valve may cause syncope. Involvement of the right heart and tricuspid valves may 
give rise to right-sided failure. The symptoms of cardiac metastases are extremely variable and 
depend on the location of the tumor. Dyspnea, palpitations, syncope, chest 8pain, and peripheral 
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edema are common clinical findings (3,4). 
Localization  
Cardiac metastases can occur either by direct extension, via the bloodstream or lymphatics, or by 
intracavitary diffusion through the inferior vena cava (IVC). Pericardial metastasis (69%) is the 
most common, followed by epicardial (34%), myocardial (32%), and endocardial metastases (5%) 
(3). The pericardium is most often involved because of direct invasion by thoracic cancer, including 
breast and lung cancer (Figure 10.1).  
 
 
Figure 10.1 Cardiac metastasis of a concealed metastatic lung carcinoma. (A) CMR myocardial 
tissue characterisation. A T2-weighted with fat saturation sequence in the long-axis view shows 
multiple hyperintense nodules; (B) an inhomogeneous uptake of gadolinium agent on postcontrast 
delayed T1 inversion recovery in the same section. Note the multiple nodules involving the full 
interventricular septum; (C) transbronchial biopsy. Histology reveals diffuse infiltration of 
irregularly shaped glands with cytological atypia (inset); (D) marked cytoplasmic immunoreactivity 
for CK7 is visible at immunohistochemistry; (E) whitish firm metastatic nodules are visible in 
transverse section of the heart at postmortem; (F) at histology, the nodules consist of neoplastic 
epithelial tissue proliferation (inset).From Perazzolo Marra et al., Circulation, 2012. 
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Abdominal and pelvic tumors may reach the right atrium through the IVC. The most common 
tumor exhibiting this tendency is renal cell carcinoma (4). A recent review suggested that in men, 
lung cancer is the most frequent cause of cardiac metastasis, followed by esophageal cancer and 
lymphoma, whereas in women, lung cancer is the most frequent, followed by lymphoma and breast 
cancer (5). 
Pathologic findings  
Metastatics deposits may be diffuse, multinodular, or consist of a single dominant mass. Especially 
with carcinomas, there may be diffuse studding and thickening of the pericardial surfaces. This 
pattern can grossly be confused with mesothelioma, or benign fibrosing pericarditis. Carcinomatous 
spread in the myocardium is frequently most prominent in subepicardial lymphatics, whereas 
melanomas, sarcomas, renal cell carcinomas, lymphoid neoplasms and intramyocardial interstitial 
tumours. The histopathologic distinction between primary and metastatic sarcoma may be 
impossible upon surgical resection of a cardiac tumour. However sarcomas metastatic to the heart 
cause symptoms at their primary site before cardiac symptoms are evident, however. Although 
primary sarcomas of the heart are uncommon, extracardiac sarcomas presenting as cardiac 
metastases are even rarer. Heart failure, cardiac arrhythmias, heart blocks, acute myocardial 
infarction, myocardial rupture, systemic embolization, and superior vena cava (SVC) syndrome 
(Figure 10.2) are other manifestations of cardiac metastases. A new heart murmur or any new ECG 
finding without clear symptoms in a cancer patient should raise suspicion for cardiac metastases. 
Typical ECG findings encountered in patients with cardiac metastases are ST-T wave changes 
(mimicking myocardial ischemia or injury), new atrial fibrillation or flutter, and low voltages, with 
electrical alternans indicating a significant pericardial effusion. ECG findings of myocardial injury 
may indicate invasion or compression of the coronary vessels by tumor (4). 
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Figure 10.2 Renal cell carcinoma (hypernephroma). A large hyperdense mass, filling almost 
completely the lumen of inferior vena cava and protruding into right atrium (arrow), can be 
appreciated at transthoracic echocardiography from both subcostal (a) and apical four-chamber 
view (b) IVC inferior vena cava, LA left atrium, LV left ventricle, RA right atrium, RV right 
ventricle. From Basso et al., Cardiac Tumor Pathology, 2013. 
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CHAPTER 11 
 
DIRECT AND INDIRECT COMPLICATIONS OF NEOPLASIA 
 
 
11.1 Cardiac Tamponade  
 
Approximately a third of patients with cardiac tumors have a pericardial involvement will initially 
be found to have impaired cardiac function, that can progress to cardiac tamponade, which demands 
immediate drainage. Symptoms include chest pain, fever, dyspnea, cough, and peripheral edema. 
Tamponade without two or more signs of an inflammatory process (typically pain, friction rub, 
fever, diffuse ST-segment elevation) is more likely to be malignant (2.9-fold increase in risk)(1). 
Physical examination, ECG, and chest radiographic findings are generally similar to those of 
pericardial effusion of any cause. Echocardiography demonstrates the effusion, which is usually 
large, although it does not have to be if the fluid has accumulated quickly. However, tamponade can 
occur with loculated effusions, and in these cases the typical echocardiographic signs may be 
absent. Acute treatment of tamponade includes careful fluid replacement as a temporizing measure 
if the patient is believed to be volume depleted with compromised hemodynamics (1). 
Echocardiography-guided pericardiocentesis is required. Fluid should be sent for a full battery of 
diagnostic tests because as noted, the cause is commonly noncancerous, even in patients with 
known cancer. If the effusion is malignant, cytologic examination of the pericardial fluid is positive 
in approximately 85% of patients. Although no randomized clinical trials using various strategies 
have been conducted, the risk for recurrence of the effusion appears to be reduced by extended 
catheter drainage (3 ± 2 days; 11.5% recurrence) as opposed to simple pericardiocentesis (2). 
Recurrence of pericardial effusion can often be treated by repeated pericardiocentesis and extended 
catheter drainage. Some have used intrapericardial instillation of chemotherapeutic agents or 
sclerosing agents, but it is not clear that this approach is more effective than extended catheter 
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drainage. Occasionally, percutaneous balloon pericardiotomy or pericardiectomy may be required, 
but patients with malignant effusions have such a poor prognosis (median survival of 135 days in 
one series of 275 patients) that invasive procedures should be avoided, if possible. Therapy is 
directed at the underlying tumor.  
 
11.2 Pericardial neoplastic involvement  
 
The differential diagnosis between malignant processes and other causes of pericarditis is 
particularly relevant and generally is accomplished by imaging, CT scan, cytology of pericardial 
fluid and eventually biopsies. Primary tumours of the pericardium, either benign (lipomas and 
fibromas) or malignant (mesotheliomas, angiosarcomas, fibrosarcomas), are very rare (3,4). 
Mesothelioma, the most common malignant tumour, is almost always incurable. The most common 
secondary malignant tumours are lung cancer, breast cancer, malignant melanoma, lymphomas and 
leukaemias. Malignant pericardial effusions may be small, medium or large, with an imminent 
tamponade (frequent recurrences) or constriction; they may even be the initial sign of malignant 
disease (5). The diagnosis is based on confirmation of the malignant infiltration within the 
pericardium (3,4). Of note, in almost two-thirds of patients with documented malignancy, 
pericardial effusion is caused by non-malignant diseases, radiation pericarditis (breast cancer and 
Hodgkin disease) , other therapies or opportunistic infections (4,6). 
 
11.3 Superior Vena Cava Syndrome  
In the midthird of the mediastinum, the left and right brachiocephalic veins join to form the SVC. 
The SVC then extends caudally, courses anterior to the right main bronchus, and terminates in the 
superior aspect of the right atrium. The SVC is joined posteriorly by the azygos vein and runs 
  113 
posterior to and to the right of the ascending aorta. During its course the SVC is adjacent to the right 
paratracheal, azygous, right hilar, and subcarinal lymph node groups. Blood flow in the venous 
system is under low pressure and the vessel itself is thin walled. Any inflammatory process in the 
mediastinum or enlargement of the lymph nodes or ascending aorta can cause the SVC to be 
compressed and result in reduced blood flow and eventually complete occlusion (Figure 11.1).  
 
 
 
Figure 11.1 Anatomy of SVC syndrome. Lymph nodes may obstruct blood return above the 
entrance of the azygos vein (A) and result in edema of the face, neck, and arms and distended veins 
in the neck and arms and over the upper part of the chest. Obstruction below the return of the 
azygos vein (B) results in retrograde flow through the azygos via collateral veins to the IVC and in 
all the symptoms and signs in A plus dilation of the veins over the abdomen as well. From Skatin AT 
Atlas of Diagnostic Oncolog, 2003. 
 
SVC syndrome was first described by William Hunter in 1757 in a patient with a syphilitic 
aneurysm of the ascending aorta. Over time, vascular causes have declined and now the most 
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common cause of SVC syndrome is malignancy, of which lung carcinoma is the most frequent, 
followed by lymphoma and metastatic cancer (7). Malignancy accounts for more than 85% of cases 
of SVC syndrome (8). Other causes of SVC syndrome, which are somewhat benign, account for 3% 
to 15% of cases and include nonmalignant causes such as thrombosis from the use of intravascular 
devices (e.g., catheters or pacemakers), infection, thymoma, substernal thyroid goiter, and aortic 
aneurysm (8). Other possibilities include disease causing systemic vasculitis, such as Behçet 
disease, and radiation-induced fibrosis. A clinical diagnosis is usually made on the basis of a 
constellation of symptoms and signs, and a classification system has been proposed (9). The 
development of SVC syndrome is generally insidious, but occasionally it may develop rapidly. The 
severity of the syndrome depends on the rapidity of onset of the obstruction and its location. The 
more rapid the onset, the more severe the symptoms because collateral veins do not have time to 
distend and accommodate the increased blood flow. A typical manifestation consist of facial edema, 
dyspnea, and cough (7,10). Facial edema is seen most frequently; it is worse in the morning and 
gets better during the day as the patient ambulates. Other symptoms that occur less frequently 
include stridor, headache, syncope, dizziness, hoarseness, and confusion (7,10). Common findings 
on examination include facial edema, distended neck and chest veins, arm edema, and facial 
plethora (7). Investigations depend primarily on whether the underlying cause is known. In a patient 
with no previous diagnosis, a chest radiograph, CT of the chest, and potentially bronchoscopy may 
reveal lung cancer as the most common cause. CT is usually very helpful because it provides a 
detailed evaluation of the venous system and also helps identify the principal causes, such as a 
neoplasm, thrombosis from central catheters, or infection resulting in sclerosing mediastinitis (11). 
Magnetic resonance venography can be used as an alternative to CT in patients with an allergy to 
contrast dye or in whom CT cannot be performed for other reasons. Intravenous venography is 
another option in patients who may not be able to undergo CT. Treatment is directly related to the 
underlying cause. In patients with known malignancy, systemic chemotherapy and radiation therapy 
are typically carried out. If the main cause of SVC obstruction is thrombosis, stent deployment is an 
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attractive option (12,13). Surgical bypass of an obstructed SVC is another option, especially if 
insufficient diagnostic tissue can be obtained by other measures.  
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CHAPTER 12 
 
SURGICAL TREATMENT of CARDIAC TUMORS 
 
As soon as the diagnosis of cardiac tumor is confirmed, the patient should be treated at an 
interdisciplinary center. It is crucial for oncologists, radiotherapists, and surgeons to cooperate 
closely as a team. Cardiac tumors present a particular challenge for heart surgeons, because great 
versatility is required. The treating cardiac center must have experience over the whole spectrum of 
heart surgery, including adult, pediatric, and rhythm surgery as well as transplantation and artificial 
heart implantation. Owing to the small numbers of cases there is no evidential basis for the optimal 
treatment regime, especially when it comes to malignant tumors (1).  
 
12. 1 Surgical tecniques 
The surgical management of cardiac tumors began in 1936 when Beck successfully resected a 
teratoma external to the right ventricle (2). In 1951 Mauer resected a left ventricular lipoma (3) and 
Bhanson and Newman in 1952 removed a large right atrial myxoma using inflow caval occlusion 
(4). In 1954 Crafoord for the first time removed successfully a left atrial myxoma using 
cardiopulmonary bypass (5), whereas Kay et al. first removed a left ventricular myxoma in 1959 
(6). By the early sixties, owing to the progressive safety of cardiopulmonary bypass and to the 
increased use of echocardiography, atrial myxomas started to be removed successfully on a more 
routine-based approach (7,8). Currently, operative excision is the treatment of choice for most 
benign cardiac tumors, very often resulting in a complete cure. Through a median sternotomy, 
intramural and intracavitary tumors must be excised under direct vision using the heart–lung 
machine (Figure 12.1) with bicaval or femoral cannulation.  
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Figure 12.1 Diagram of a cardiopulmonary bypass circuit. Venous blood is drained from the venae 
cavae/right atrium into the venous reservoir which is incorporated in the membrane 
oxygenator/heat exchanger unit. Arterialized blood exits the oxygenator and passes through a filter/ 
bubble trap to the aortic cannula, which is usually placed in the ascending aorta. Suction systems 
and sources of gases are also represented. From Basso et al., Cardiac Tumor Pathology, 2013. 
 
After establishing cardiopulmonary bypass, under mild hypothermia, the heart is separated from the 
systemic circulation by an aortic cross-clamp followed by the infusion of blood or crystalloid 
cardioplegia administered antegradely into the aortic root, and/or retrogradely into the coronary 
sinus. Although some epicardial tumors may be removed without the aid of extracorporeal cir- 
culation, intramural and intracavitary tumors must be excised under direct vision. The surgical 
approach will depend on the location of the cardiac mass (right, left, combined atriotomy, 
aortotomy, etc.). In view of the potential multifocal location of the cardiac tumors, all the cardiac 
chambers will need to be systematically explored. A good surgical exposure represents the 
fundamental principle to accomplish a complete, possibly en bloc, resection of the tumor. The ideal 
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resection aims to include the tumor and a portion of the cardiac wall and/or interatrial septum, to 
which it is attached, spared by the disease. To overcome the technical challenges of complete 
resection with accurate cardiac reconstruction, particularly of left-sided tumors with posterior 
extension, a technique of cardiac explantation, ex vivo tumor resection with cardiac reconstruction, 
and cardiac reimplantation cardiac autotransplantation has been successfully utilized (9-11). Every 
care should be taken to remove the tumor without fragmentation. The use of an intra-aortic filter 
(Edwards Embol-X System, Edwards Lifescience, Irvine CA) may help to reduce the event of 
systemic embolization in case of friable tumors located in the left cardiac chambers (12). 
Ventricular tumors are usually approached through the AV valves if located in the ventricular 
inflow, or through the semilunar valves when located in the ventricular outflow tract. In the event of 
tumors involving a cardiac valve, the surgical strategy should still aim to a complete resection of the 
mass, although trying to preserve the native valve by means of several well-described reparative 
techniques. When this is not possible, a valve prosthesis may be used.  
Simple tumor resection  
Simple resection is generally selected for benign tumors such as myxomas. Care must be exercised 
in connecting the heart–lung machine to avoid dislodging any tumor material. For this reason we 
open both atria from the right superior pulmonary vein without injuring the tumor or its base. The 
tumor and its root can then be removed from the septum in toto. We always inspect all the chambers 
of the heart to exclude the presence of further tumors (13). The defect is closed with patch material. 
Apart from the usual risks involved in the use of a heart–lung machine this intervention is relatively 
uncomplicated.  
Complex tumor resection  
Complex tumor resection is possible to provide when the mass is confined to the heart and, if 
malignant, has not infiltrated the adjacent tissues. In advanced tumors involving the right side of the 
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heart the whole right half of the organ can be resected. Pulmonary blood flow is assured by means 
of Fontan circulation, well known from pediatric heart surgery (13, 14). Chronic right heart failure 
may result.  
Ex-situ resection  
In the event that the tumor involves the posterior wall of the left atrium or the dorsal great vessels, 
the heart can be removed from the thorax to facilitate complete resection. Attempts at conventional 
surgery in such circumstances are hampered by an inadequate view of the tumor, leading to 
incomplete resection and an unfavorable long-term outcome. Lifting the heart out of the body 
means it can be turned for optimal visualization of all structures. Following tumor resection the 
cardiac anatomy is restored using artificial materials (prostheses, patches, valves) or biological 
tissue before the heart is reimplanted (Figure 12.1) (15-18). Depending on the amount of cardiac 
tissue excised, left and/or right heart failure may result as a secondary complication.  
 
Implantation of an artificial heart  
If the tumor also involves the left heart, and there are no metastases, the implantation of a total 
artificial heart (TAH) can be considered as a treatment of last resort—especially in younger 
patients. The principal complications following successful implantation are hemorrhages, 
thromboses, infections, and, as a result of the necessary anticoagulation, embolisms (19).  
Heart transplantation  
Heart transplantation (HTx) can occasionally be considered as a final treatment option in individual 
cases, provided distant metastases can be ruled out (19). One significant risk of this procedure is the 
danger of exacerbation of undetected micrometastases by the necessary immunosuppression.  
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Figure 12.1 Explanted heart after ex-situ resection of a sarcoma and implantation of a mitral 
valve (MV) before cardiac reimplantation (LA, resection margin, left atrium; Ao, aorta; PA, 
pulmonary artery; arrow, cardioplegia catheter). From Hoffmeier A, et al., Dtsch Arztebl Int, 
2014. 
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12.2 Surgical Benign Tumors 
a. Myxoma  
Surgical resection is the only effective therapeutic option for patients with cardiac myxoma and 
should not be delayed because death from obstruction to flow within the heart or embolization may 
occur in as many as 8% of patients awaiting operation (20-22). A median sternotomy approach with 
ascending aortic and bicaval cannulation usually is employed (Figure 12.2). Manipulation of the 
heart before initiation of cardiopulmonary bypass is minimized in deference to the known friability 
and embolic tendency of myxomas. Left atrial myxomas can be approached by an incision through 
the anterior wall of the left atrium, anterior to the right pulmonary veins, eventually 
extended behind both cavae to achieve greater exposure. Exposure of left atrial myxomas is 
maximized by using several principles from mitral valve repair surgery. Removal of large tumors 
attached to the interatrial septum however may be facilitated by a right atrial approach, 
which allows easy removal of tumor attached to the fossa ovalis with full-thickness and 
large excision at the site of attachment and easy patch closure of the atrial septum if 
necessary (Figure 12.3, 12.4,12.5, 12.6) (23). As mentioned, the tumor should be removed 
without fragmentation. Nevertheless, after removal the surgical field should be irrigated and 
inspected for loose fragments. In case of atrial wall rather than septal attachment, large full-
thickness excision of tumor insertion should be aimed whenever possible. A systematic 
inspection of the other cardiac chambers to exclude other tumor location potentially 
overlooked by the utilized imaging techniques is always recommended.  
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Figure 12.2 Standard venous cannulation for atrial myxomas and right 
arteriotomy site for left atrial myxoma. Superior vena cava cannulation allows 
increased right atrial exposure or division of superior vena cava for additional 
left atrial exposure. 
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Figure 12.3 Left atriotomy and exposure of myxoma. 
 
Figure 12.4 Removal of large left atrium myxoma. 
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Figure 12.5 Left atrium myxoma.  
 
  
  
Figure 12.6 Repair of atrial septum with pericardial patch after removal of myxoma  
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About 10 to 20% of all cardiac myxomas are found in the right atrium (24). Right atrial myxomas 
pose special venous cannulation problems, and intraoperative echocardiography may be of benefit 
in allowing safe cannulation. Both venae cavae may be cannulated directly. When low-or high-lying 
tumor pedicles preclude safe transatrial cannulation, cannulation of the jugular or femoral vein can 
provide venous drainage of the upper or lower body. In general, we always can cannulate the 
superior vena cava distal enough from the right atrium to allow adequate tumor resection, but 
occasionally femoral venous cannula drainage has been necessary for low-lying right atrial tumors 
encroaching on the inferior vena caval orifice. If the tumor is large or attached near both caval 
orifices, peripheral cannulation of both jugular and femoral veins may be used to initiate 
cardiopulmonary bypass and deep hypothermia. The right atrium may be opened widely for 
resection of the tumor and reconstruction of the atrium using pericardium or 
polytetrafluoroethylene, keeping in mind that resection of large or critically placed right atrial 
myxomas may require careful preoperative planning and special perfusion strategies. Because 
myxomas rarely extend deep in the endocardium, it is not necessary to resect deeply around the 
conduction tissue. The tricuspid valve and the right atrium, as well as the left atrium and ventricle, 
should always be inspected carefully for multicentric tumors in patients with right atrial myxoma, 
with or without familial occurrence (23,25,26). The surgeons policy is to resect full thickness 
whenever possible. However, only partial-thickness resection of the area of tumor attachment has 
been performed when anatomically necessary without a noted increase in recurrence rate (27,28). 
Ventricular myxomas (6–8%) occur more often in women and children and may be multicentric 
(29-33). Right ventricular tumors typically arise from the free wall, and left ventricular tumors tend 
to originate in the vicinity of the posterior papillary or at the apex (32). Ventricular myxomas 
usually are approached through the atrioventricular (AV) valve or by detaching the anterior portion 
of the AV valve for exposure and resection and reattachment after resection (34). Occasional small 
tumors in either outflow tract can be removed through the outflow valve (34,35). If necessary, the 
tumor is excised through a direct incision into the ventricle, but this is unusual. It is not necessary to 
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remove the full thickness of the ventricular wall because no recurrences have been reported with 
partial thickness excisions. As with right atrial myxoma, the presence of ventricular myxoma 
prompts inspection for other tumors because of the high incidence of multiple tumors. Overall 30-
day mortality after removal of an atrial myxoma is below 5%, although excision of ventricular 
myxomas carries a higher risk (approximately 10%). Operative mortality may be increased by 
tumor unrelated variables such as advanced age, disability, and/or comorbidities. Long-term 
survival, freedom from complication, and quality of life are excellent in the nonfamilial form of 
myxoma (36, 14, 23, 25, 28, 36, 37). The recurrence of an intracardiac myxoma (described by 
6 months and up to 11 years after the resection) may be related to an inadequate original 
resection, when at the same site of the original tumor, or to the presence of neoplastic 
fragments. Recurrence of nonfamilial sporadic myxoma is approximately 1–4% and 
possibly lower in patients with a normal DNA genotype (28,38). The rarer subgroup of 
patients with sporadic myxoma and abnormal DNA have a recurrence rate estimated at 
between 12 and 40%. The recurrence rate is highest in patients with familial complex 
myxomas, all of whom exhibit DNA mutation (38). Overall, recurrences are more common 
in younger patients. Most recurrent myxomas occur in the same or different cardiac 
chambers, and may be multiple particularly in familial complex myxomas. Extracardiac 
recurrence after myxoma excision, likely from embolization, with local tumor growth, and 
invasion, has been observed in the brain, arteries, soft tissue, and bones (24).  
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b) Minimally invasive approaches to surgical removal 
Minimally invasive approaches are being applied with increasing frequency in all areas of cardiac 
surgery, and cardiac tumors are no exception. Experience is confined to benign tumors and is quite 
limited. Approaches have included right parasternal or partial sternotomy exposure with standard 
cardioplegic techniques (39),  right submammary incision with femoral-femoral bypass and 
nonclamped ventricular fibrillation (40) and the right submammary port access method with 
antegrade cardioplegia and ascending aortic balloon occlusion (41). Minimally invasive cardiac 
surgery may be used in a selected group of patients with cardiac tumors (Figure 12.7, 12.8). 
Thoracoscopic techniques have been used to aid in visualization and removal of ventricular 
fibroelastomas (42,43). There have been case reports of myxoma removal via thoracoscopy (44,45). 
It is important to remember that use of a minimally invasive technique must not compromise 
complete surgical excision. Results in this limited number of selected patients have been good, but 
more experience and longer follow-up are needed before this can be recommended as a standard 
approach.  
Figure 12.7 Minimally invasive cardiac surgery. 
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Figure 12.8 Minimally invasive cardiac surgery for removal cardiac myxoma. 
 
12.3 Other Benign Cardiac Tumors  
Large tumors that produce severe symptoms should be resected. Smaller, asymptomatic tumors 
encountered unexpectedly during cardiac operation should be removed if excision can be performed 
without adding risk to the primary procedure. These tumors are not known to recur.  
a. Papillary Fibroelastoma 
Papillary fibroelastomas are the most common tumors of the cardiac valves, accounting for 75% of 
all valvular tumors. Papillary fibroelastomas of the cardiac valve, affect mainly the aortic or the 
mitral valve, even though tricuspid and pulmonary valves may also be affected, should be resected 
whenever diagnosed because of their known tendency to produce life-threatening complications. 
Valve repair rather than replacement should follow the resection of these benign tumors whenever 
technically feasible, using conservative margins of resection (Figure 12.9,12.10). Occasionally, 
papillary fibroelastomas locate in the left ventricle, more often in the outflow tract, can be 
multifocal, and are associated with the hypertrophic obstructive cardiomyopathy (46-48). 
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Figure 12.9 Resection of aortic Papillary Fibroelastoma. 
 
Figure 12.10 Aortic Papillary Fibroelastoma.  
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b. Lipoma  
Lipomas are well encapsulated primary benign cardiac tumors, and consist of mature fat cells (29, 
49-51). They are usually located in the subepicardium, in the left ventricle, in the right atrium, and 
in the interatrial septum. The non-encapsulated hypertrophy of the fat within the atrial septum, often 
in continuity with the epicardial of the right AV sulcus, is known as lipomatous hypertrophy. Large 
lipomas, particularly when associated with severe symptoms, should be resected. Smaller, 
asymptomatic tumors, incidentally discovered during cardiac operation undertaken for different 
indications, should be removed if excision is doable without adding risk to the primary procedure. 
In case of location in the atrial septum, patch reconstruction may be necessary. Cardiac lipomas are 
not known to recur.  
 
c. Rhabdomyoma  
Rhabdomyoma represents the most common cardiac tumor in children. Thought to be a myocardial 
hamartoma rather than a true neoplasm (52, 53), it usually presents during the first few days after 
birth. Occasionally sporadic, it is quite often associated with tuberous sclerosis (hereditary disorder 
characterized by hamartomas, seizures, developmental delay and behavioral problems, sebaceous 
adenomas) (54, 55). Early operation is recommended in patients who do not have tuberous sclerosis 
before 1 year of age. The tumor usually is removed easily in early infancy, and some can be 
enucleated. Unfortunately, symptomatic tumors often are both multiple and extensive, particularly 
in patients with tuberous sclerosis, who, unfortunately, have a dismal long-term outlook. In such 
circumstances, surgery offers little benefit. The tumor is removed easily in early infancy, and 
despite being non-encapsulated some can be completely resected. Partial resection may be 
conceivable to release the obstruction (56). However, whenever planning a surgical strategy, it has 
to be considered that rhabdomyomas may regress spontaneously after birth, thus limiting indication 
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to surgical resection to the actual symptomatic cases (Figure 12.11)(57).  
 
Figure 12.11 Cardiac MRI investigation. A, ECG-triggered breath-hold proton density T1-
weighted fast spin echo in coronal plane, showing a large homogeneous isointense mass involving 
the LV wall. B, ECG-triggered breath-hold cine steady-state free procession in axial plane, 
showing the cardiac mass involving the interventricular septum. C, ECG-triggered breath-hold cine 
steady state free procession in 4-chamber view, showing no intracardiac obstruction. D, After 
gadolinium injection, no mass hyperenhancement is visible. Ao indicates aorta; RA, right atrium; 
RV, right ventricle; LA, left atrium; LV, left ventricle. From Padalino M. et al., Circulation, 2011. 
 
 
 
d.  Fibroma 
Fibromas are the second most common cardiac tumor of childhood, although they may also affect 
the adult population. These are solitary non-infiltrating intramural tumors, usually located in the left 
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ventricle, mainly in the interventricular septum, and they are often mistaken for hypertrophic 
cardiomyopathy or apical thrombus.   
Surgical excision is successful in some patients, particularly if the tumor is localized, does not 
involve vital structures, and can be enucleated (58-61).   
Video-assisted cardioscopy has been recently reported as a suitable and useful technique to assist 
removal of primary left ventricular fibroma with intracavitary extension (62). Complete excision is 
usually curative. On the other hand, partial tumor removal is palliative although often followed by a 
prolonged survival (63). Children with extensive fibromas, in good overall clinical conditions and 
with no specific contraindications, have been successfully treated with orthotopic cardiac 
transplantation (64). In selected cases of extensive right ventricular tumors, a right heart bypass 
(cavo-pulmonary anastomosis) has also been utilized as a palliative solution or as a bridge to 
orthotopic cardiac transplantation (65).  
 
e. Haemangioma 
The tumors can be resected in asymptomatic patients, and cardiopulmonary bypass is 
recommended. Meticulous ligation of feeding vessels is required to prevent postoperative residual 
arteriovenous fistulas or intracavity communications. Partial resections have produced long-term 
benefits. Tumors rarely resolve spontaneously (66,67).  
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12.4 Surgical Malignant Primary Cardiac Tumors 
Malignant cardiac tumors continue to pose a therapeutic challenge to cardiac surgeons and 
oncologists because of the technical difficulty involved in extensive cardiac resections and the 
aggressive biological nature of the tumors. Primary malignant tumors are relatively rare, accounting 
for up to 25% of all primary cardiac tumors in third level referral centers. They usually affect 
people aged 30–50 years, and are mainly represented by sarcomas (angiosarcoma, 
rhabdomyosarcoma, leiomyosarcoma, liposarcoma, osteosarcoma, fibrosarcoma, and malignant 
fibrous histiocytoma) and lymphomas (49-51). Angiosarcomas are usually located in the right 
chambers of the heart, whereas other sarcomas affect the left atrium more frequently. Lymphomas 
with bi-atrial localization have also been reported (68). Malignant tumors have usually a poor 
prognosis in view of the extensive infiltration of the myocardium, the frequent obstruction of 
intracardiac flow, and the occurrence of metastases. The decision to resect a primary malignant 
tumor is based on several variables, including tumor location and size, histology, grade of 
myocardial infiltration, relationship with the cardiac valves and the fibrous skeleton of the heart, 
absence of metastatic spread, and potential for a radical excision of the mass. Other more general 
variables, such as age, overall clinical conditions, frailty, and comorbidities, will also need to be 
considered to finalize the surgical strategy (68-74). Currently, chemotherapy, radiation therapy, or a 
combination of both are used as an adjuvant to decrease tumor size and facilitate surgical resection. 
In this perspective, a multidisciplinary decision-making approach relative to the overall therapeutic 
management is mandatory. If complete resection is possible, respecting the anatomical and 
functional integrity of the heart, surgery provides better palliation and can improve survival vs. 
medical therapy alone (68-74). To overcome the technical challenges of complete resection with 
accurate cardiac reconstruction, particularly of left-sided tumors with posterior extension, a 
technique of cardiac explantation, ex vivo tumor resection with cardiac reconstruction, and cardiac 
reimplantation—cardiac autotransplantation—has been utilized (69,70,75). Surgical outcomes with 
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cardiac auto-transplantation are excellent in patients who do not require concurrent pneumonectomy 
(69). In selected cases of right ventricular tumors, a right heart bypass (cavo-pulmonary 
anastomosis) has also been utilized as a palliation to prolong survival (22). The role of orthotopic 
cardiac transplantation in the management of locally advanced non-metastatic cardiac tumors 
appears to be limited. Indeed, it has been shown that about two-thirds of the so treated patients die 
of local recurrence or distant metastases within a year. Nevertheless, about 25% of the patients 
managed by orthotopic cardiac transplantation have a mean survival of more than 2 years without 
recurrent disease (70, 76).  
 
a. Angiosarcoma 
These tumors tend to be bulky and aggressively invade adjacent structures, including the great 
veins, tricuspid valve, right ventricular free wall, interventricular septum, and right coronary artery 
(77). Obstruction and right-sided heart failure are not uncommon. Pathologic examination of 
resected specimens demonstrates anastomosing vascular channels lined with typical anaplastic 
epithelial cells. Unfortunately, most of these tumors have spread by the time of presentation, usually 
to the lung, liver, and brain (78). Without resection, 90% of the patients are dead within 9 to 12 
months of diagnosis despite radiation or chemotherapy (78). We have seen carefully selected 
patients without evidence of spread on metastatic evaluation who have undergone complete surgical 
resection with subsequent chemotherapy (Figure 12.12). Surgical resection may include the right 
atrium. In addition, right coronary bypass and even tricuspid valve repair or replacement may be 
undertaken. We have had no hospital mortality in this small group, and the main problem remains 
metastasis rather than recurrence at the local site.  
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Figure 12.12: (A) Right atrial angiosarcoma involving right coronary artery and tricuspid valve. 
(B) Excision of tumor with right coronary artery and tricuspid valve. (C) Tricuspid valve replaced. 
(D) Completed repair using bovine pericardium and perfomed bypass graft. (Copyright 2002, 
Baylor College of Medicine.). From: Walkes JC et al., Cardiac surgery in the adult, 2008.  
 
 
 
b. Rabdomiosarcoma 
The tumors are aggressive and may invade pericardium. Surgical excision of small tumors may be 
rational, but local and distant metastases and poor response to radiation or chemotherapy limit 
survival to less than 12 months in most of patients (79,80).  
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12.5 Other Sarcomas and Mesenchymal-Origin Tumors  
Myosarcoma, liposarcoma, osteosarcoma, chondro-myxosarcoma, plasmacytoma, and 
carcinosarcoma arising from the heart all have been reported, but by the time diagnosis is made, 
only palliative therapy usually can be offered, and surgery is indicated only occasionally (81,82). 
Regardless of therapy, it is unusual for patients with these diagnoses to survive more than a year.  
 
a. Lymphomas  
Lymphomas may arise primarily from the heart, although this is rare (83). Most of these tumors 
respond to radiation and chemotherapy. Even when complete resection is not possible, and 
incomplete resection is performed to relieve acute obstructive systems, radiation and chemotherapy 
have allowed for up to 3-year survival in selected patients.  
 
12.6 Secondary Metastatic Tumors  
Metastatic cardiac tumors are far more frequent (approximately from 20-fold) than primary tumors 
of the heart. Although almost every type of malignant tumor has the potential to reach the heart, 
they usually arise from melanomas, lung, breast, and renal cancer, as well as lymphomas. 
Metastases may originate from blood dissemination via coronary arteries (melanoma, sarcoma, 
bronchogenic carcinoma) or lymphatic channels of cancer cells, direct extension via adjacent tis- 
sues (lung, breast, esophageal, and thymic tumors), or propagation via the superior or the inferior 
vena cava to the right atrium (liver, kidney tumors). The pericardium is most often affected by 
direct extension of thoracic cancer, resulting in pericardial effusion which may contain masses 
comprising either cancer cells or blood clots and fibrin. The myocardium is the target of 
hematologous and/or retrograde lymphatic metastasis. Surgical therapy is limited to relief of 
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recurrent pericardial effusions or, occasionally, cardiac tamponade. In most instances, these patients 
have widespread disease with limited life expectancies. Surgical therapy is directed at providing 
symptomatic palliation with minimal patient discomfort and hospital stay. This is most readily 
accomplished via subxiphoid pericardiotomy, which can be accomplished under local anesthesia if 
necessary with reliable relief of symptoms, a recurrence rate of about 3%, and little mortality (83). 
Alternatively, a large pericardial window in the left pleural space can be created using thoracoscopy 
(84), but we would recommend this only under unusual circumstances. This can be accomplished 
with minimal patient discomfort but does require general anesthesia with single-lung ventilation and 
may be poorly tolerated by patients with hemodynamic deterioration secondary to large effusions. 
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CHAPTER 13 
 
MEDICAL THERAPY AND CARDIOTOXICITY 
 
 
Malignant cardiac tumors are usually sarcomas or Non-Hodgkin Lymphomas (NHL). The treat- 
ment of NHL is based on chemotherapy (CT), and surgery is commonly used as a rescue therapy to 
treat severe hemodynamic impairment by a large mass. Although sarcomas are very rare and large 
institutions usually see roughly one patient/year or less, it impossible to plan randomized studies to 
assess the best treatment approach (1-5). Cardiac sarcomas are a small subgroup of the more 
frequent sarcomas of other sites (they represent roughly 1/100 of all sarcomas), and in most cases 
they pertain to the soft tissue sarcomas (STS) group. Therefore, the basic therapeutic approach 
should be based on extrapolation of data from the most frequent tumor sites, including STS of the 
extremities and trunk (2, 5-7). In fact, cardiac sarcomas are at higher risk of recurrence and they 
have a worse prognosis compared to STS of other more frequent anatomical sites, including 
extremities, superficial trunk, retroperitoneum, and head and neck (7). The standard treatment for 
localized STS consists of adequate surgery with extensive resection followed by postoperative 
radiation therapy (RT) in most cases. Preoperative RT may be an option for large tumors or more 
critical tumor sites where surgery may not be radical (8,9). The role of adjuvant CT has not been yet 
defined so far, but clinical practice guidelines include it as an option in high- risk patients (9,10). 
The particular location of cardiac sarcomas makes both surgery with curative intent and the use of 
RT particularly challenging. While CT is mandatory in metastatic and/or locally advanced, 
unresectable disease, its use has been proposed for some critical locations, such as right 
heart/pulmonary artery sarcomas, attempting to increase the number of resections with negative 
margins (11,12).  
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Therefore, a multimodality approach, including CT and/or RT before or after surgery, has been used 
by several authors even for localized, non-metastatic tumors, and it seems to be effective in 
prolonging both time to relapse and survival in some selected studies.  The outcome data reported in 
different papers are conflicting for some reasons: a wide variety of tumor presentations (metastatic 
vs. non-metastatic, high-grade vs. low or intermediate grade, right vs. left heart, surgery limited to 
the heart or including the lung);  a non-standard surgical approach; and, in most studies, a 
multimodality therapy is limited to patients with incomplete resection or metastatic disease (11, 13-
25). Overall, when comparing studies with a multimodality approach, regardless of the surgical 
outcome, and historical studies with CT used in some subgroups of patients only, there seems to be 
a favorable trend for the multi-modality approach (21-25).  
The most common regimen for soft tissue sarcoma treatment is combined doxorubicin and 
ifosfamide but anthracycline chemotherapy is both cardiotoxic and a radiation sensitizer (26). 
Nevertheless, an initial large meta-analysis of adjuvant chemotherapy trials has shown no survival 
benefit of adjuvant chemotherapy for adult soft tissue sarcomas (27). 
Planning the best treatment strategies for primary cardiac sarcoma will need improved 
understanding of natural history and prognostic factors of this very rare disease. Thus, patients 
should be referred to treatment in specialised centres, and multicentre data poolong should be 
coordinated through intergroup reseaech organisations.  
 
Cardiotoxicity  
 
Most of the treatments have a considerable risk of cardiac toxicity, but this risk should be balanced 
with the risk of tumor progression. Since the survival is usually limited to few years, the main 
concern is to prevent short- and medium-term toxicity. CT adverse effects may be prevented with 
careful dosage of drugs, cardioprotective agents, and strict monitoring of cardiac function. Short- 
and medium-term cardiac toxicity of RT may be limited using modern radiation techniques. A 
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number of new targeted therapies are under evaluation and will hopefully improve the outcome of 
this severe pathology.  
Coronary artery disease, valvular heart disease, and constrictive pericarditis are the typical chronic 
side effects affecting long-term survivors: they become clinically evident usually 10 years after the 
treatment, with increasing incidence at longer follow-up (28). The first acute effect of irradiation is 
a pro-inflammatory effect, with endothelial damage of medium-large vessels and microvessels, 
pericarditis, and myocarditis (28-30). Pericardium is the most frequently affected site: acute 
pericarditis is associated with edematous swelling of the pericardial layers: it may be present in a 
painless effusive form with spontaneous recovery, or as an acute fibrinous pericarditis that can be 
cured with Nonsteroidal Anti-inflammatory Drugs. In both cases, pericardial effusion is usually 
mild to moderate, and in 80% of cases there are no reliquates, while in the remaining 20% the 
disease evolves toward a constrictive pericarditis (31). The microvessel damage is followed by a 
persistent decrease in capillary density and eventually leads to chronic myocardial ischemia and 
degeneration; an impairment in myocardial perfusion may be observed in the first months after RT, 
even if the increased risk of clinically evident RT-linked ischemic heart disease becomes 
statistically significant only after 10 years (30, 31-34).   
The cardiotoxicity of CT are various and depending of treatment used. In fact, it has been studied 
for decade as damage site effect control of Doxorubicin (DOX) and other anthracyclines 
(ANTHRA). These damage of myocytes is both iron-dependent and iron-independent (35-37). 
Ultrastructural early alteration in damaged myocytes consists of distension of sarcoplasmic 
reticulum to form sarcoplasmic vacuoles, followed by myofibrillar lysis and focal proliferation of 
sarcoplasmic reticulum, disruption of myofibrils, atrophy, and necrosis; interstitial edema and 
eventually fibrosis are observed in more severe forms. Myocardial damage has been reported as 
most severe in the left ventricle (LV) and in the ventricular septum, intermediate in the right 
ventricle and the left atrium, and at least in the right atrium (38). Each single dose of DOX causes 
an irreversible cardiac damage; for this reason the cardiotoxicity is cumulative, even for CT given 
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many years apart. The final effect is a diastolic and systolic left ventricular dysfunction and, in the 
most advanced stages, a congestive heart failure (CHF).  
The main reported toxicities of ifosfamide (IFO) are nephrotoxicity and neurotoxicity. From the 
cardiac point of view it has been usually considered safe, but cardiac toxicity in high-dose (>10 
g/m2) treated patients has been reported, and it is significant (>10%) when using >15 g/m2 (39-42). 
Taxane cardiotoxicity is mostly evident as a self-limiting supraventricular arrhythmias (atrial 
fibrillation, sinus bradycardia), but they may also increase DOX (much less EpiDOX) toxicity, 
altering ANHTRA pharmacokinetics and possibly promoting the formation of toxic metabolites 
(35,36,41). Finally, Vascular Endothelial Growth Factor Blocking Agents and Tyrosine Kinase 
Inhibitors (VEGF block) (by the monoclonal antibody Bevacizumab and the tyrosine kinase 
inhibitors (TKI) Sunitinib and Sorafenib) causes hypertension (mainly by reducing the nitric oxide 
release by the endothelial cells, by interfering with renal physiology, and by increasing the vascular 
resistance), thromboembolism, and hemorrhages (43-45).  
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CHAPTER 14 
 
FUTURE DIRECTIONS 
 
The clinical outcome of patients with a primary cardiac tumor depends heavily on early detection 
and prompt, appropriate treatment. It is a frequent phenomenon that cardiac tumors are discovered 
only after a patient experiences a period characterized by a confusing constellation of symptoms 
that are ultimately connected to abnormal findings on an image suggestive of a cardiac tumor. As a 
result, an advanced stage of disease is already commonly present at the time of diagnosis. Over the 
last few years the increasing use of imaging modalities (e.g., echocardiography, MRI, and CT) has 
led to an increasing number of incidental findings of primary cardiac tumor. However, current 
imaging techniques can accurately differentiate tumors from other causes of masses seen on 
imaging only slightly more than 50% of the time. It is hoped that with improvement in 
echocardiography, CT, and MRI techniques, all cardiac tumors would be identified with a high 
degree of certainty. There is no non-invasive technique that can identify whether the tumor is 
benign or malignant, and therefore a pathologic sample is needed in all cases. Improvement in 
surgical technique has led to minimally invasive approaches, but this still entails general anesthesia 
and a surgical incision and is the source of major stress for a patient. Continued refinement of 
surgical tools and approaches will lead to less morbidity and mortality (1). Transvenous biopsy of 
the cardiac mass for pathologic confirmation (under echocardiographic guidance) is done at some 
centers. Refinement of this technique will enable better sampling in the future. In some centers, 
PET is routinely used to evaluate for metastatic disease. Currently, no blood tests are available that 
would point to metastasis.  
Better noninvasive imaging of tumor extension is needed because at present only a minority of 
patients with right-sided heart sarcoma have a pathologically negative margin after resection, and 
the use of neoadjuvant chemotherapy in selected cases may provide better results, but outcomes 
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need to be reported in a disciplined manner (2). All patients should be managed by a 
multidisciplinary team that includes medical oncologists, radiation oncologists, cardiologists, and 
cardiac surgeons. Over next few years it is hoped that better targeted therapy will be developed that 
will inhibit or arrest the malignant proliferating endothelial cells. Cardiac autotransplantation, 
which was originally performed by Dr. Cooley in 1984 (3), is now a standard practice for complex 
cases in some centers. With further improvement in surgical techniques, chemotherapy, and 
radiation therapy, the overall prognosis of patients with cardiac tumors will continue to improve.  
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PART II 
EPIDEMIOLOGY AND SURGICAL PATHOLOGY OF  
PRIMARY CARDIAC TUMORS  
IN VENETO REGION OF ITALY (2005-2016) 
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THE AIM OF THE STUDY 
 
The study has been divided into two phases:  
1. The first one consisted in the creation of a Registry of Primary Cardiac Tumors in the Veneto 
Region, involving all Cardiac Surgery Centers and Pathological Anatomy Units, by performing an 
epidemiological analysis. 
2. The second phase aimed to analyze the short and long-term results of the surgical treatment of 
cardiac tumor using a retrospective analysis over a range of 12 years of experience in three Cardiac 
Surgery Centers of the Veneto Region. The results will be analyzed in terms of short and long term 
mortality, tumor recurrence rates, re-intervention freedom and all preoperative, intraoperative and 
postoperative variables conditioning the results. 
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MATERIALS AND METHODS 
 
This study was a multi-center, retrospective study over 12 years (2005-2016). All patients who 
underwent cardiac surgery due to a primary cardiac tumor confirmed by pathology in the Veneto 
Region at the Centers for Cardiac Surgery and Pathological Anatomy of Mestre, Treviso, Mirano, 
Padova, Vicenza and Verona were included for analysis. All eligible records from the selected 
hospitals were reviewed: (1) demographic characteristics and possible risk factors at the time of 
diagnosis, including age, gender, height and weight, occupation, family history of tumor (whether 
malignant or benign, occurred on parents or siblings), smoking habit; (2) clinical features, including 
primary tumor sites; (3) results of imaging tests, including ultrasound, CT, MRI; (4) use of currently 
available treatment approaches, including surgery, chemotherapy, biological therapy and target 
therapy; (5) pathological characteristics, including tumor size, infiltration, mitosis rate, Ki-67 
labeling index. 
The cardiac surgery and pathological anatomy databases were used to identify the patients who 
were diagnosed with primary cardiac tumors, and then the detailed medical records of these patients 
were reviewed with special attention to confirm the presence, location and histological type of the 
tumors.  
Surgical treatment was performed through extracorporeal-circulation, aortic clamping and 
cardioplegic arrest by anterograde or retrograde with cold blood or crystalloid cardioplegia. After 
the removal of the heart tumor by the anchorage site and the size was reconstituted with the base of 
the plant with or without the use of an autologous pericardial patch, equine or bovine pericardium 
patches or patches of synthetic material (Dacron). Mininvasive approach was performed with 
Heartport Access system and video-assisted thoracoscopic surgery. 
Pathological materials from all patients studied were available for gross and histological 
examinations. Specimens were fixed in formalin, routinely processed for light microscopy and 
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stained with hematoxylin-eosin, Alcian-periodic acid-Schif (PAS), Heidenhaim trichrome and 
Weigert van Gieson. When required, transmission electron microscopy and immunohistochemistry 
studies were performed to confirm the histological diagnosis. 
Follow-up information was obtained from subsequent medical examination or phone-call. 
 
Statistical Analysis  
 
To evaluate the effects of various clinical variables on postoperative death and complications/ 
adverse events (such as cardiac/non–cardiac-related death, reoperation, recurrence of 
cardiac/noncardiac tumor) at follow-up, we applied the following statistical tests. 
 Log-rank test and Fisher’s exact test were used to test effect of clinical variables on survival. 
Because the precise chronology of adverse events was not always known, we included all 
complications and adverse events occurring during follow-up. 
Finally, McNemar test was used to determine a significant difference of 2 major clinical variables 
(NYHA class and Ejection fraction) before and after surgical repair, early and late. Survival curves 
were constructed with Kaplan-Meier estimates. Probability values <0.05 were considered 
statistically significant. Analyses were performed using SAS System, version 9.2.  
 
 
  
  164 
SURGICAL PATHOLOGY OF PRIMARY CARDIAC TUMORS 
 
RESULTS 1 
Epidemiological and Surgical Pathology of findings of the whole cohort 
 
In the Registry of Primary Cardiac Tumors in the Veneto Region, the study population included 279 
patients, 254 patients (91.03%) were affected by benign primitive cardiac tumors and 25 patients 
(8.97%) by malignant cardiac tumors. The Table 1 and Figure 1 list the number of tumors and case 
distribution per year in the 6 Cardiac Surgery Centers (Table 1, Figure 1).  
 
Table1 Frequence of surgically resected primary cardiac tumors in the Veneto 
Region Population (2005-2016). 
 
Cardiac Surgery 
Units  in Veneto 
Region 
Benign 
Tumors 
2005-2016 
Malignant 
Tumors 
2005-2016 
Total 
Padova 79 6 85 
Mestre 33 2 35 
Mirano 10 1 11 
Treviso 30 2 32 
Verona 50 8 58 
Vicenza 52 6 58 
Total 254 (91.03%) 25 (8.97%) 279 (100%) 
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According to the Census Data of Veneto Region, the median of resident population was 4.876.601 
in the time interval 2005-2016.   The incidence of primary cardiac tumors in Veneto Region was 
constant every years and the average incidence in the general population is 0.47% (from 0,33% to 
0,64%), 47 cases per 100.000 in men and women. 
 
Figure 1 Number of cases per year of surgically resected primary cardiac tumors in the Veneto 
Region (2005-2016).  
 
  
The mean age of 59.8±16.8 years (ranging from 1 month to 83 years), 155 female (55.6%). Our 
series showed that frequency of primary cardiac tumors was quite different among age groups 
with the highest in the age group 60–70 years (n=75, 26,88%). In this age range there were 71 
benign tumors and only 5 were malignant. Cardiac myxoma has a peak of incidence between the 
fifth and sixth decades of life. Rhabdomyoma and fibroma are the most common benign cardiac 
tumors in children: 2 rhabdomyoma where only in age group 0-10 years, and the ages were for 
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both 4 months; there are only one case fibroma in the same age group and the age was 2 years old  
(Figure 2).     
 
Figure 2 Distribution of Primary Cardiac Tumors in Veneto Region by Age Groups (2005-
2016). 
 
 
The majority of primary cardiac tumors were benign, with the most common being myxoma (n= 
178, 70,08%). The remaining benign tumors included papillary fibroelastoma (n= 48, 18,90%), 
lipoma (n=8, 3,15%), hemangioma (n=7, 2,76), pericardial cyst (n=5, 1,97%), inflammatory 
miofibroblastic tumor (n=3, 1,18%), rhabdomyoma (n=2, 0,79%), fibroma (n=1, 0,39%) and other 
benign tumors (n=2, 0,79%)(Figure 3 and Table 2).  
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Figure 3 Benign Cardiac Tumors in Veneto Population. 
 
Table 2 Benign Cardiac Tumors in Veneto Population. 
 
178 
48 
8 
7 
5 
3 
2 
1 
2 
Myxoma
Papillary fibroelastoma
Lipoma
Hemangioma
Pericardial Cyst
Inflammatory myofibroblastic tumor
Rhabdomyoma
Fibroma
Other Benign Tumors
N° cases of Primary Benign Cardiac Tumors 
Number of Primary Benign Cardiac Tumors
 Myxo
ma 
Papill
ary 
Fibro
elasto
ma 
Lipoma Hem
angio
ma 
Perica
rdial 
Cyst 
Inflammat
ory 
Myofibro
balstic 
Fibroma Leiomyo
ma 
Rhabdo
myoma 
TOT 
N 
% 
Padova 46 15 3 7 4 1 1 0 2 79 
(31,1
%) 
Mestre 25 6 2     0 0 0 0 0 0 33 
(13,0
%) 
Mirano 8 2 0 0 0 0 0 0 0 10  
(3,9
%) 
Treviso 26 2 1 0 0 1 0 0 0 30 
(11,8
%) 
Verona 41 5 2 0 1 1 0 0 0 50 
(19,7
%) 
Vicenza 32 18 0 0 0 0 0        1        0 52 
(20,5
%) 
 178 
(70,08
%) 
48 
(18
,90
%) 
8 
(3,15%
) 
7 
2,76
%) 
5 
(1,97
%) 
3 
(1,18%) 
1 
(0,39%) 
2 
(0,79%) 
2 
(0,79%) 
254  
(100
%) 
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Cardiac myxoma is the most frequent primary cardiac tumor and have a costant frequency in the 
time interval considered compared with all other tumors (Figure 4). 
Figure 4 Frequency of Myxoma and Other primary benign tumors in Veneto Region Population  
(2005-2016).  
 
 
The majority were female (103, 57,86%), the age range was 5-83 years (mean 62,06±14,4).  
Myxoma is the paradigm of intra-cavitary cardiac tumour, mostly arising in the left atrium followed 
by the right atrium, and only occasionally the ventricles. In our experience, myxoma was located in 
the left atrium in 91% of cases (162/178) and in the right atrium in 9% (Figure 5). 
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Figure 5 Location of atrial myxoma. 
 
 
 
 
 
 
 
 
 
 
 
Papillary fibroelastoma is the second primary cardiac tumour in our series (N=48, 18,9%). All of 
the 48 patients have been surgically resected, 24 female, age ranging from 28 to 83 years, mean 
62,5±14,9 years. The most common location was the valvular endocardium, 83.3% arising in the 
left heart, in particular aortic valve (n=23, 47.9%), mitral valve (n=13, 27.1%); tricuspid valve (n=6, 
12.5%) and pulmonary valve (n=1, 2.1%) were less frequently involved. Seven patients have mural 
endocardium location (4 lefts ventricle, 3 right atrium)(Figure 6). 
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Figure 6 Location of Papillary fibroelastoma. 
 
 
Primary malignant cardiac tumours are very rare, representing nearly 10% of all primary cardiac 
neoplasms. The population consists of 25 patients, 13 male and 12 female. Primary cardiac 
sarcomas can occur at any age, but are more frequently diagnosed between the third and fifth 
decades, and equally in men and women. The age ranging was 18-80 years, mean 52,52±16,1. The 
most prevalent histotype was angiosarcoma (n=8, 32.5%) followed by primary cardiac lymphoma 
(n=6, 24%), leiomyosarcoma (n=3, 12%) and synovial sarcoma (n=4, 16%) represented the main 
malignant primary cardiac tumours in our population, as shown in Table 3 and Figure 7. Tumor 
location was the left atrium in four (one leiomyosarcoma, one intimal sarcoma and two synovial 
sarcoma); the right atrium in six (five angiosarcoma and one B cell lymphoma); the bi-atrium in 
five (one angiosarcoma, one B cell lymphoma, one synovial sarcoma and two leiomyosarcoma); the 
right ventricle in four (three lymphoma, one intimal sarcoma); the right heart in two 
(angiosarcoma); and the pericardium in two (one myofibroblastic malignant tumor, one 
condrosarcoma); finally in one  synovial sarcoma and in one lymphoma cardiac involvement was 
diffuse.  
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Table 3  Surgically Resected Primary Malignant Cardiac Tumors in Veneto Population. 
 
Figure 7 Surgically Resected Primary Malignant Cardiac Tumors in Veneto Population.  
 
 
 
 
 Angiosarco
ma 
Cardiac 
Lympho
ma 
Leiom
yosarc
oma 
Synovi
al 
Sarco
ma 
Intima
l 
Sarco
ma 
Condrosarco
ma 
Myofibrobla
stic 
Malignant 
tumor 
TOT 
N% 
Padova 2 1 1 1 0 0 1 6  
(24,0%) 
Mestre 1 0 0 1 0 0 0 2  
(8,0%) 
Mirano 0 1 0 0 0 0 0 1  
(4,0%) 
Treviso 0 0 0 1 1 0 0 2  
(8%) 
Verona 5 3 0 0 0 0 0 8  
(32,0%) 
Vicenz
a 
0 1 2 1 1 1 0 6  
(24,0%) 
 8 
(32.0%) 
6 
(24.0%) 
3 
(12%) 
4 
(16%) 
2 
(8%) 
1 
(4.0%) 
1 
(4.0%) 
25 
(100%) 
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RESULTS 2  
Clinical, Surgical and Follow-up Data of the subgroup cohort 
 
From January 01, 2005 to December 2016, the subgroup of 79 consecutive patients underwent 
cardiac surgery for primary cardiac tumors at three Cardiac Surgery Units (Mestre, Mirano, 
Treviso) of Veneto Region. Of the 79 operated patients, 74 (93.7%) had a primary benign tumor 
and 4 (6.3%) a malignant tumor. Benign tumors included myxomas (n=61, 77.21%), papillary 
fibroelastoma (n=10, 12.65%), lipomas (n=3, 3.79%), pericardial cyst (n=1, 1.29%). Malignant 
tumors (n=4, 5.06%) included angiosarcoma (n=1, 25%), synovial sarcoma (n=2, 50%), intimal 
sarcoma (n=1, 25%), primary cardiac lymphoma (n=1, 25%) (Figure 8). 68 patients (86%) were 
operated by standard sternotomy and 11 patients (14%) with mininvasive approach including 6 with 
Heartport Access system and video-assisted thoracoscopic surgery. 16 patients (20%) underwent an 
associated procedure (coronary artery bypass grafting, aortic valce replacement, mitral valve repair 
or replacement and tricuspid valve repair). 
Figure 8 Frequency of the primary cardiac tumors in the surgical series, three 
Cardiac Surgery Units (Mestre, Mirano, Treviso) of Veneto Region. 
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Overall, the mean age at tumor diagnosis was 63.3±15.2 years and females were affected in 51.9%. 
The most common presenting symptoms were dyspnea (n=19, 24.1%), thromboembolic event (n=7, 
8.9%), and chest pain (n=23, 29.1%); 11.4% (n=9) of patients presented in New York Heart 
Association (NYHA class) III/IV. Cardiovascular risk factors included hypertension in 53.2% 
(n=42), coronary artery disease in 25.3% (n=20). Clinical data of patients are shown in Table 4A. In 
survival analysis, none of the clinical variables considered was statistically significant. Moreover, 
comparing myxomas and other primary benign cardiac tumors, no significant difference was found 
in cardiovascular risk factors, apart from a higher incidence of hypertension in patients affected by 
myxomas. All of the patients were diagnosed with echocardiography and angiography, cardiac MRI was performed in 6 patients (7.6%).  
Tumor and hemodynamic characteristics are shown in Table 5A and 5B. Associated valve diseases did not correlate neither with the development of a cardiac tumor nor with the outcome of the patients who underwent tumor resection.  
There was significant correlation between tumor histotype and location in the heart. Specifically, left (n=59, 74,7%) and right atrial tumors (n=7, 8,9%) were primarily myxomas, whereas valvular tumors were predominantly papillary fibroelastomas. There was a relatively equal distribution of the various histological subtypes of ventricular tumors; however, cardiac fibromas occurred exclusively in the ventricle. Additionally, primary tumors of the great arteries were malignant. There was a higher incidence of mitral regurgitation in patients with left atrial and aortic valve tumors.  
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Table 4A Comparison of the clinical features in relation of survival of the 3 Center Surgical series.   
Clinical features (n=79) P-Value Total (N=79) Death (N=9) Alive (N=70) 
     
Age at Surgey (Mean ± SD 
(N)) 
0,52 63.3 ± 15.2 
(N=79) 
68.1 ± 6.6 
(N=9) 
62.6 ± 15.9 (N=70) 
Age (Median (min-max))   67.0 (10.0-83.0) 70.0 (57.0-
77.0) 
66.5 (10.0-83.0) 
          
Sex         
Male 0,3 38 (48.1%) 6 (66.7%) 32 (45.7%) 
Female   41 (51.9%) 3 (33.3%) 38 (54.3%) 
Risk factors         
Hypertension 0,49 42 (53.2%) 6 (66.7%) 36 (51.4%) 
Coronary artery disease 1,00 20 (25.3%) 2 (22.2%) 18 (25.7%) 
          
          
Preoperative symptoms         
Asymptomatic 0,64 13 (16.5%) 2 (22.2%) 11 (15.7%) 
          
New York Heart Association 
classification (NYHA class) 
0,92       
I   13 (16.5%) 2 (22.2%) 11 (15.7%) 
II   21 (26.6%) 2 (22.2%) 19 (27.1%) 
III   8 (10.1%) 1 (11.1%) 7 (10.0%) 
IV   1 (1.3%) 0 (0.0%) 1 (1.4%) 
          
Syncope 0,31 3 (3.8%) 1 (11.1%) 2 (2.9%) 
          
Chest pain 0,44 23 (29.1%) 4 (44.4%) 19 (27.1%) 
     
Cerebral Events  1,00 5 (6.7%) 0 (0.0%) 5 (7.6%) 
          
Previous Cancer 1,00 67 (100.0%) 5 (100.0%) 62 (100.0%) 
     
Presenting Symptoms 0,38       
Incidental   19 (24.1%) 4 (44.4%) 15 (21.4%) 
Dyspnea   19 (24.1%) 1 (11.1%) 18 (25.7%) 
Angor   7 (8.9%) 1 (11.1%) 6 (8.6%) 
Lipothymia   2 (2.5%) 1 (11.1%) 1 (1.4%) 
Arrhythmia   8 (10.1%) 0 (0.0%) 8 (11.4%) 
Barkin Cough   1 (1.3%) 0 (0.0%) 1 (1.4%) 
Thromboembolism   7 (8.9%) 0 (0.0%) 7 (10.0%) 
Dyspnea and angor   11 (13.9%) 2 (22.2%) 9 (12.9%) 
Pulmonary Edema   5 (6.3%) 0 (0.0%) 5 (7.1%) 
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Table 4B Comparison of the clinical features of patients of the 3 Center surgical series affected by 
myxomas vs patients affected by other benign primary cardiac tumors. 
  
 Clinical features 
 (N=75) 
 
 
 
P-Value 
 
Total (N=75) 
 
Myxoma (N=61) 
 
Other Benign 
Tumors (N=14) 
      
Age at Surgery (Mean ± SD 
(N)) 
0.75 63.6 ± 15.5 
(N=75) 
64.4 ± 13.9 (N=61) 60.2 ± 21.5 (N=14) 
Age (Median (min-max))   69.0 (10.0-83.0) 69.0 (19.0-83.0) 66.5 (10.0-81.0) 
      
Sex 0,25    
Male   38 (50.7%) 33 (54.1%) 5 (35.7%) 
Female   37 (49.3%) 28 (45.9%) 9 (64.3%) 
Risk factors     
Hypertension 0,0074 41 (54.7%) 38 (62.3%) 3 (21.4%) 
Coronary artery disease 0,095 20 (26.7%) 19 (31.1%) 1 (7.1%) 
      
Preoperative symptoms     
Asymptomatic 0,44 13 (17.3%) 12 (19.7%) 1 (7.1%) 
      
New York Heart Association 
classification (NYHA class) 0,27    
I  13 (17.3%) 13 (21.3%) 0 (0.0%) 
II  20 (26.7%) 16 (26.2%) 4 (28.6%) 
III  7 (9.3%) 6 (9.8%) 1 (7.1%) 
IV  1 (1.3%) 1 (1.6%) 0 (0.0%) 
      
Syncope 0,47 3 (4.0%) 2 (3.3%) 1 (7.1%) 
      
Chest pain 0,52 21 (28.0%) 16 (26.2%) 5 (35.7%) 
  
    
Cerebral Events  0,56 4 (5.6%) 3 (5.2%) 1 (7.7%) 
      
Previous Cancer 0,56 64 (100.0%) 53 (100.0%) 11 (100.0%) 
      
Presenting Symptoms 0,83    
Incidental   19 (25.3%) 15 (24.6%) 4 (28.6%) 
Dyspnea  18 (24.0%) 16 (26.2%) 2 (14.3%) 
Angor  7 (9.3%) 5 (8.2%) 2 (14.3%) 
Lipothymia  2 (2.7%) 2 (3.3%) 0 (0.0%) 
Arrhythmia  7 (9.3%) 6 (9.8%) 1 (7.1%) 
Barkin Cough  1 (1.3%) 1 (1.6%) 0 (0.0%) 
Thromboembolism  7 (9.3%) 5 (8.2%) 2 (14.3%) 
Dyspnea and angor  9 (12.0%) 8 (13.1%) 1 (7.1%) 
Pulmonary Edema  5 (6.7%) 3 (4.9%) 2 (14.3%) 
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Table 5A Echocardiographic and Hemodynamic Characteristics by Tumor Location. 
   
Clinical  features (n=79) P-Value Total (N=79) Death (N=9) Alive (N=70) 
          
Ejection Fraction (Mean ± SD 
(N)) 
0.40 58.6 ± 8.6 
(N=78) 
56.3 ± 10.6 
(N=9) 
58.8 ± 8.3 (N=69) 
Ejection Fraction (Median (min-
max)) 
  60.0 (30.0-74.0) 58.0 (45.0-
74.0) 
60.0 (30.0-73.0) 
          
Aortic stenosis 1,00 3 (3.8%) 0 (0.0%) 3 (4.3%) 
          
Aortic regurgitation 0,15       
I-II   8 (10,2%) 2 (22.2%) 6 (8.6%) 
III-IV   1 (1.3%) 0 (0.0%) 1 (1.4%) 
          
Mitral regurgitation 1,00       
I   24 (30.4%) 3 (33.3%) 21 (30.0%) 
II   9 (11.4%) 1 (11.1%) 8 (11.4%) 
II   3 (3.8%) 0 (0.0%) 3 (4.3%) 
IV   1 (1.3%) 0 (0.0%) 1 (1.4%) 
          
Mitral stenosis 1,00 3 (3,8) 0 (0.0%) 3(3,8) 
          
Tricuspid regurgitation 1,00       
I   12 (15.2%) 1 (11.1%) 11 (15.7%) 
II   7 (8.9%) 1 (11.1%) 6 (8.6%) 
III   1 (1.3%) 0 (0.0%) 1 (1.4%) 
IV   1 (1.3%) 0 (0.0%) 1 (1.4%) 
Position in the heart 0,25       
Left Atrium   59 (74.7%) 7 (77.8%) 52 (74.3%) 
Right Atrium   7 (8.9%) 0 (0.0%) 7 (10.0%) 
Ventricle   4 (5.1%) 0 (0.0%) 4 (5.7%) 
Valve   8 (10.1%) 1 (11.1%) 7 (10.0%) 
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Table 5B Echocardiographic and Hemodynamic Characteristics by Benign Cardiac Tumor Location. 
 
 
 
    
Clinical features (n=75) P-Value Total (N=75) 
Myxoma 
(N=61) 
Other Benign 
Tumors 
(N=14) 
     
Ejection Fraction (Mean ± SD (N)) 0,09 58.7 ± 8.6 
(N=74) 
58.1 ± 8.5 
(N=60) 
61.6 ± 9.2 
(N=14) 
Ejection Fraction (Median (min-max))   60.0 (30.0-74.0) 60.0 (30.0-
73.0) 
65.0 (38.0-
74.0) 
      
Aortic stenosis 0,47 3 (4.0%) 2 (3.3%) 1 (7.1%) 
      
Aortic regurgitation 0,56    
I-II  8 (10,6%) 8 (13.1%) 0 (0.0%) 
III-IV  1 (1.3%) 1 (1.6%) 0 (0.0%) 
      
Mitral regurgitation 0,39    
I  22 (29.3%) 17 (27.9%) 5 (35.7%) 
II  9 (12.0%) 6 (9.8%) 3 (21.4%) 
II  3 (4.0%) 2 (3.3%) 1 (7.1%) 
IV  1 (1.3%) 1 (1.6%) 0 (0.0%) 
      
Mitral stenosis 1,00 3 (4,0%) 3 (4,9%) 0 (0.0%) 
         
Tricuspid regurgitation 0,01    
I  11 (14.7%) 7 (11.5%) 4 (28.6%) 
II  7 (9.3%) 3 (4.9%) 4 (28.6%) 
III  1 (1.3%) 1 (1.6%) 0 (0.0%) 
IV  1 (1.3%) 1 (1.6%) 0 (0.0%) 
Position in the heart     
Left Atrium <.0001 58 (77.3%) 57 (93.4%) 1 (7.1%) 
Right Atrium 0.31 6 (8.0%) 4 (6.6%) 2 (14.3%) 
Ventricle 0.033 2 (2.7%) 0 (0.0%) 2 (14.3%) 
      
Papillary Fibroelastoma <.0001       
Aortic valve   4 (5.3%) 0 (0.0%) 4 (28.6%) 
Mitral Valve   3 (4.0%) 0 (0.0%) 3 (21.4%) 
Tricuspid valve    3 (4.0%) 0 (0.0%) 3 (21.4%) 
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Surgical Approach and Resection  
 
Table 6A and 6B show the comparison of operative characteristics between alive and dead patients 
who urderwent cardiac surgery for primary cardiac tumors. Surgical approaches and methods of 
extracorporeal circulation do not appear to affect survival. In particular, there was no significant 
difference in cardiopulmonary bypass (CPB) time (p=0,31) and cross-clamp time (p=0,46). As the 
majority of tumors is represented by mixoma (n=61, 77,21%), left atriotomy (n=49, 80,3%) is the 
most used intracardiac surgical approach . The majority of tumors into the atrium, mitral valve, and 
tricuspid valve tumors were resected by a single atrial approach, whereas aortic valve tumors were 
commonly resected via aortotomy. Ventricular tumors demonstrated the greatest variety of resection 
techniques; approximately one third were resected by ventriculotomy; however, other techniques 
such as extracardiac resection, atrial, and aortic approaches were also used. The majority of tumors 
were completely resected with negative margins. Cardiac reconstruction with prosthetic material 
was commonly performed after atrial tumor resection. Conversely, ventricular reconstruction with 
prosthetic material was uncommon. Valve procedures also varied according to tumor location 
(Table 6C).  
The incidence of the major postoperative complication was 8.8% (n=7), and included bleeding 
requiring reoperation, renal insufficiency requiring dialysis, and acute myocardial infarction 
requiring angiografy and stent implantation. 31.6% (n=25) of patients had an arrhythmias, the most 
common being atrial fibrillation. Peri-operative (30 day) mortality was equal to 1.3% (n=1). After 
discharge, one patients with a diagnosis of a malignant tumor underwent adjuvant chemotherapy 
and radiotherapy. 
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Table 6A Comparison of operative characteristics in relation of survival of patients who urderwent 
cardiac surgery for primary cardiac tumors in the 3 Center.  
Operative 
Characteristics (n=79) P-Value Total (N=79 Death0/(N=9) Alive (N=70) 
     
CBP time, minutes (Mean 
± SD (N)) 
0,31 70.7 ± 42.3 (N=71) 50.3 ± 35.0 (N=7) 73.0 ± 42.7 
(N=64) 
CBP time, minutes 
(Median (min-max)) 
  58.0 (0.0-205.0) 58.0 (0.0-106.0) 57.5 (10.0-
205.0) 
          
Cross-clamp Time, 
minutes (Mean ± SD (N)) 
0,46 53.4 ± 36.4 (N=71) 38.7 ± 29.5 (N=7) 55.0 ± 36.9 
(N=64) 
Cross-clamp Time, 
minutes (min-max) 
  43.0 (0.0-185.0) 48.0 (0.0-72.0) 42.5 (0.0-185.0) 
     
Incision         
Sternotomy 1 68 (86.1%) 8 (88.9%) 60 (85.7%) 
Minitoracotomy   11 (13.9%) 1 (11.1%) 10 (14.3%) 
          
Approch of CBP 0,29       
Central   67 (84.8%) 7 (77.8%) 60 (85.7%) 
Peripheral   10 (12.7%) 1 (11.1%) 9 (12.9%) 
Beating Heart  1 (1.3%) 1 (1.6%) 0 (0.0%) 
     
Concommitant Procedures 0,66 16 (20.5%) 2 (25.0%) 14 (20.0%) 
          
Septum tumor 
implantation 
0,056 52 (65.8%) 3 (33.3%) 49 (70.0%) 
          
Approach      
Single atriotomy left 0.42 57 (75.0%) 7 (77.8%) 50 (74.6%) 
Single atriotomy right   10 (13.2%) 2 (22.2%) 8 (11.9%) 
Biatriotomy   9 (11.8%) 0 (0.0%) 9 (13.4%) 
     
ICU stay, days (Mean ± 
SD (N)) 
0.97 2.0 ± 2.8 (N=79) 4.0 ± 7.5 (N=9) 1.8 ± 1.3 (N=70) 
ICU saty, days (Median 
(min-max)) 
  2.0 (0.0-24.0) 2.0 (1.0-24.0) 2.0 (0.0-10.0) 
          
Ejection fraction 
postoperative  (Mean ± 
SD (N)) 
0.11 59.4 ± 7.3 (N=79) 54.2 ± 11.1 (N=9) 60.1 ± 6.5 
(N=70) 
Ejection fraction 
postoperative  (Median 
(min-max)) 
  60.0 (38.0-70.0) 55.0 (38.0-70.0) 60.0 (38.0-70.0) 
          
Hospital stay, days (Mean 
± SD (N)) 
0.21 8.6 ± 3.7 (N=79) 10.7 ± 5.9 (N=9) 8.4 ± 3.3 (N=70) 
  180 
Hospital stay, days 
(Median (min-max)) 
  8.0 (4.0-24.0) 8.0 (5.0-24.0) 8.0 (4.0-21.0) 
     
No Cardiac complications 0,42       
    78 (100.0%) 9 (100.0%) 69 (100.0%) 
          
Cerebral complications  0,42 0 (0,00%) 0 (0,00%) 0 (0,00%) 
          
Aortic regurgitation 
postoperative 
0,13       
I   6 (7.6%) 1 (11.1%) 5 (7.1%) 
II   2 (2.5%) 1 (11.1%) 1 (1.4%) 
          
Mitral regurgitation 
Postoperative 
0,11       
I   23 (29.1%) 1 (11.1%) 22 (31.4%) 
II   1 (1.3%) 0 (0.0%) 1 (1.4%) 
III-IV   1 (1.3%) 1 (11.1%) 0 (0.0%) 
          
Tricuspid regurgitation 
Postoperative 
0,04       
I   18 (22.8%) 1 (11.1%) 17 (24.3%) 
II   3 (3.8%) 2 (22.2%) 1 (1.4%) 
          
ECG Postoperative 1,00       
0   67 (84.8%) 8 (88.9%) 59 (84.3%) 
1   10 (12.7%) 1 (11.1%) 9 (12.9%) 
2   2 (2.5%) 0 (0.0%) 2 (2.9%) 
          
Pacemaker implantation 1,00 4 (5.1%) 0 (0.0%) 4 (5.7%) 
          
Discharge  0,005       
Alive   78 (98.7%) 8 (88.9%) 70 (100.0%) 
          
CBP: Cardiopulmonary Bypass; ICU: Intensive Care Unit. 
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Table 6B Comparison of operative characteristics between patients affected by myxomas vs patients 
affected by other benign tumors in the 3 Center.  
Operative Characteristics 
(n=75) P-Value Total (N=75) 
Myxoma (N=61) Other Benign 
Tumors (N=14) 
      
CBP time, minutes (Mean ± SD 
(N)) 
0.41 70.8 ± 41.4 
(N=67) 
72.1 ± 40.5 
(N=54) 
65.5 ± 46.0 
(N=13) 
CBP time, minutes (Median 
(min-max)) 
  58.0 (10.0-
205.0) 
58.0 (26.0-205.0) 54.0 (10.0-165.0) 
      
Cross-clamp Time, minutes 
(Mean ± SD (N)) 
0.46 53.0 ± 35.2 
(N=67) 
54.3 ± 34.7 
(N=54) 
47.9 ± 38.5 
(N=13) 
Cross-clamp Time, minutes (min-
max) 
  42.0 (0.0-
185.0) 
43.5 (0.0-185.0) 38.0 (0.0-131.0) 
      
Incision 0,2    
Sternotomy   64 (85.3%) 54 (88.5%) 10 (71.4%) 
Minitoracotomy   11 (14.7%) 7 (11.5%) 4 (28.6%) 
      
Approch of CBP 0.14    
Central  64 (85.3%) 54 (88.5%) 10 (71.4%) 
Peripheral  10 (13.3%) 6 (9.8%) 4 (28.6%) 
Beating Heart  1 (1.3%) 1 (1.6%) 0 (0.0%) 
      
Concommitant Procedures 1.00 15 (20.3%) 12 (20.0%) 3 (21.4%) 
      
Septum tumor implantation <.0001 51 (68.0%) 49 (80.3%) 2 (14.3%) 
      
Approach     
Single atriotomy left  54 (75.0%) 49 (80.3%) 5 (45.5%) 
Single atriotomy right  9 (12.5%) 3 (4.9%) 6 (54.5%) 
Biatriotomy  9 (12.5%) 9 (14.8%) 0 (0.0%) 
      
ICU stay, days (Mean ± SD (N)) 0.88 2.1 ± 2.8 
(N=75) 
2.2 ± 3.1 (N=61) 1.7 ± 1.0 (N=14) 
ICU saty, days (Median (min-
max)) 
  2.0 (0.0-24.0) 2.0 (0.0-24.0) 2.0 (0.0-4.0) 
      
Ejection fraction postoperative  
(Mean ± SD (N)) 
0.65 59.6 ± 7.4 
(N=75) 
59.4 ± 7.6 (N=61) 60.1 ± 6.7 (N=14) 
Ejection fraction postoperative  
(Median (min-max)) 
  60.0 (38.0-
70.0) 
60.0 (38.0-70.0) 59.5 (50.0-70.0) 
      
Hospital stay, days (Mean ± SD 
(N)) 
0.33 8.7 ± 3.8 
(N=75) 
8.6 ± 4.0 (N=61) 8.9 ± 2.9 (N=14) 
Hospital stay, days (Median 
(min-max)) 
  8.0 (4.0-24.0) 8.0 (4.0-24.0) 8.0 (5.0-16.0) 
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 No Cardiac complications 0.0006 74 (100.0%) 60 (100.0%) 14 (100.0%) 
      
      
 No Cerebral complications  0.0006 75 (100.0%) 61 (100.0%) 14 (100.0%) 
      
Aortic regurgitation postoperative 1.00    
I  6 (8.0%) 5 (8.2%) 1 (7.1%) 
II  2 (2.7%) 2 (3.3%) 0 (0.0%) 
      
Mitral regurgitation Postoperative 0.55    
I  21 (28.0%) 19 (31.1%) 2 (14.3%) 
II  1 (1.3%) 1 (1.6%) 0 (0.0%) 
III-IV  1 (1.3%) 1 (1.6%) 0 (0.0%) 
      
Tricuspid regurgitation 
Postoperative 
0.16 
   
I  17 (22.7%) 11 (18.0%) 6 (42.9%) 
II  3 (4.0%) 3 (4.9%) 0 (0.0%) 
         
ECG Postoperative     
0 0,18 64 (85.3%) 51 (83.6%) 13 (92.9%) 
1  9 (12.0%) 9 (14.8%) 0 (0.0%) 
2  2 (2.7%) 1 (1.6%) 1 (7.1%) 
      
Pacemaker implantation 0.57 4 (5.3%) 3 (4.9%) 1 (7.1%) 
      
Discharge  1.00    
Alive  74 (98.7%) 60 (98.4%) 14 (100.0%) 
      
CBP: Cardiopulmonary Bypass; ICU: Intensive Care Unit. 
 
 
 
 
 
 
 
 
 
  183 
Table 6C  Operative procedures 
Operative Data Number 79 patients  
STERNOTOMY vs MINITORACOTOMY 68/11 (6 port-access) 
CBP Time, minutes 70.7 ± 42.3 
 CCA Time, minutes 53.4 ± 36.4 
Atrium Access  (Left/Right+Left) 49 (62,02%) / 9 (11,39) 
 Beating Heart 7 (8,86%) 
Peripheral Cannulation 11 (13,92%) 
Central Cannulation 68 (86,07%) 
Reoperation 1 (1,26%) 
CABG 7 (8,86%) 
Mitral valve repair 3 (3,79%) 
Tricuspid valve repair 2 (2,53%) 
Cryoablation tumor site 4 (5,06%) 
CBP: Cardiopulmonary Bypass; CCA: Aortic Cross-Clamp; CABG: coronary artery bypass graft.  
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Survival Analysis  
The average time of follow-up was 70 months (range 1 to 138 months). It was performed at clinical 
examination or with a telephone interview. It was performed in 100% of the population. Follow-up 
features are described in the following tables (Table 7A, 7B). 
 
Figure 7A Comparison of follow-up clinical in relation of survival of patients who underwent cardiac 
surgery for cardiac tumor excision. 
Follow-up (FU) 
(N=70/79) P-Value Total (N=79 Death0/(N=9) Alive (N=70) 
          
Aortic regurgitation FU   11 (15.7%) 0 (0.0%) 11 (15.7%) 
          
Mitral regurgitation FU   23 (32,8) 0 (0.0%) 23 (32,8) 
          
Masses recidives FU 1,00 2 (2.5%) 0 (0.0%) 2 (2.9%) 
          
ECG FU         
RS   59 (84.3%) 0 (0.0%) 59 (84.3%) 
Atril Fibrillation   6 (8.6%) 0 (0.0%) 6 (8.6%) 
PM   5 (7.1%) 0 (0.0%) 5 (7.1%) 
          
New York Heart 
Association Classification 
(NYHA class) 
        
0   27 (38.6%) 0 (0.0%) 27 (38.6%) 
I   37 (52.9%) 0 (0.0%) 37 (52.9%) 
II   6 (8.6%) 0 (0.0%) 6 (8.6%) 
          
Cardiac complications  
FU   1 (1.6%) 0 (0.0%) 1 (1.6%) 
          
Ejection fraction FU 
(Mean ± SD (N)   61.2 ± 6.3 (N=70)   61.2 ± 6.3 (N=70) 
     
FU: Follow-up. 
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Figure 7B Comparison of follow-up clinical features between patients affected by myxomas and patients 
affected by other benign cardiac tumors. 
Follow-up (FU) (N=70/79) P-Value Total (N=75) Myxoma (N=61) Other Benign Tumors (N=14) 
          
Aortic regurgitation FU 0.44 11 (16.4%) 8 (14.8%) 3 (23.1%) 
          
Mitral regurgitation FU 0.099    
I  21 (31.3%) 19 (35.2%) 2 (15.4%) 
II   1 (1.5%) 0 (0.0%) 1 (7.7%) 
       
Masses recidives FU 1.00 1 (1.3%) 1 (1.6%) 0 (0.0%) 
          
ECG FU 0.69       
RS   56 (83.6%) 44 (81.5%) 12 (92.3%) 
Atril Fibrillation   6 (9.0%) 6 (11.1%) 0 (0.0%) 
PM   5 (7.5%) 4 (7.4%) 1 (7.7%) 
          
New York Heart Association 
Classification (NYHA class) 0.20       
0   26 (38.8%) 18 (33.3%) 8 (61.5%) 
I   35 (52.2%) 30 (55.6%) 5 (38.5%) 
II   6 (9.0%) 6 (11.1%) 0 (0.0%) 
          
Cardiac complications  FU 0.20 61 (100.0%) 51 (100.0%) 10 (100.0%) 
          
          
Ejection fraction FU (Mean ± 
SD (N)) 0.63 
61.3 ± 6.4 
(N=67) 61.4 ± 6.7 (N=54) 61.0 ± 5.5 (N=13) 
Ejection fraction FU (Median 
(min-max)   
62.0 (38.0-
72.0) 62.5 (38.0-72.0) 62.0 (50.0-70.0) 
     
FU: Follow-up. 
 
The following chart shows the survival curve of the entire population: after surgical resection, long-
term survival was satisfactory, equal to 77.64% (Figure 9). Figure 10 shows the survival curve 
between patients with benign tumors versus patients with malignant tumors. Malignant tumors, 
showed as expected worse long-term survival than benign ones, due to malignant biology and 
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incomplete resection. In contrast, benign tumors are not characterized by infiltrative growth and 
therefore surgery is technically simpler and radical in most cases. 
 
 
Figure 9 Survival curve of the entire population after benign and malignant tumors surgical 
resection. 
 
Figure 10 Survival curve between patients with  benign tumors versus patients with 
malignant tumors after surgical resection. 
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Further analysis has been made on the freedom of relapse and therefore of reintervention. In the 
entire population, only two patients underwent re-intervention for tumor recurrence (1 recurrent 
myxoma and 1 angiosarcoma).  
The deceased patients in the population are 9 (11%). In most cases, death was caused by extra-
cardiac malignancies (n=5). There was 1 intra-hospital death due to sepsis. In 3 cases it was not 
possible to determine the causes of death in the long term. 
By comparing clinical variables in relation to survival, Ejection Fraction (FE Basal/FE Postop 
p=0,3688; FE Basal/FE FU p=0,0067) and NYHA class (p=0,0235) both improved over time with a 
statistically significant trend (Table 8A, 8B, Table 9). 
 
Table 8A, 8B  A. Basal Ejection Fraction vs Postoperative Ejection Fraction. B Basal Ejection Fraction vs 
Follow-up Ejection Fraction.  Evaluated by Wilcoxon Test. 
A 
Variable 
 
 
N 
 
 
 
Mean 
 
 
Std 
Dev 
 
 
Minim
um 
 
Maximum 
 
Median 
 
 
Lower 
Quartile 
 
 
Upper 
Quartile 
 
 
p-value 
Wilcoxon 
signed 
rank test 
 
FE 
FE Postop   
FE Basal  
78
   
78
   
78 
58.55
   
59.41
   
-0.86 
8.57
   
7.35
   
6.42 
30.00   
38.00   
-20.00 
74.00   
70.00   
20.00 
60.00   
60.00 
0.00 
55.00   
57.00   
-2.00 
65.00   
65.00   
0.00 
0.3688 
0,3688 
B 
Variable 
 
 
N 
 
 
 
Mean 
 
 
Std 
Dev 
 
 
Minimum 
 
Maximum 
 
Median 
 
 
Lower 
Quartile 
 
 
Upper 
Quartile 
 
 
p-value 
Wilcoxon 
signed 
rank test 
 
FE 
FE 
FU   
FE 
Basal  
69 
69 
69 
58.84   
61,13   
-2,29 
8.31   
6,33   
6.83 
30.00   
38.00   
-22.00 
73.00   
72.00   
12.00 
60.00   
62.00 
0.00 
56.00   
60.00   
-5.00 
65.00   
65.00   
0.00 
0.3688 
0,0067 
 
Wilcoxon Test is a statistical comparison non parametric that applies in the case of a single sample (FE 
Ejection Fraction) with two paired measurements. FE: Ejection Fraction; FE Basal: Basal Ejection Fraction; FE Postop: Postoperative Ejection Fraction; FE FU: Follow-up Ejection Fraction. 
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Table 9 NYHA Class Basal versus Follow-up (p=0,0235). Evaluated by extension 
McNemar test (Bowman Test). 
 
NYHA Class Basal vs NYHA Class FU 
McNemar 
test 
extension 
p=0,0235 
N=70 
Frequency of 
Classes 0 I+II III+IV Total 
0 12 37,50 
20 
62,50 
0 
0,00 32 
I+II 13 43,33 
17 
56,67 
0 
0,00 30 
III+IV 2 25.00 
6 
75,00 
0 
0,00 8 
Total 27 43 0 70 
(Bowman Test) McNemar test extension was used to determine a statistical 
relation between  identical variables belonging to the same population, before and 
after an event, such as cardiac surgery. NYHA Class: New York Heart 
Association; FU: Follow-up. 
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DISCUSSION AND CONCLUSIONS 
 
Epidemiological data of primary cardiac tumours are still based on post-mortem studies. The 
incidence and prevalence of cardiac neoplasms, in general, have shown little change over time. 
Since the early report in 1934 (1-3), the reported prevalence is very low, ranging from 0.0017 to 
0.28% in autopsy series, with the variability being strongly influenced by when and where the data 
have been collected and according to diagnostic methods (4-6). In fact, some years later the era of 
“surgical pathology” started with the advent of cardiac imaging and open heart surgery, when 
cardiac neoplasms were diagnosed during life and not only in the autopsy room and became 
surgically resectable with excellent long-term survival. Cardiac non invasive imaging through 
transthoracic and transesophageal echocardiography easily detects heart masses. Cardiac magnetic 
resonance imaging and computed tomography are helpful complementary investigations, for 
refining diagnosis and in the post-surgery follow-up. Histology with immuno-histochemistry of any 
cardiac mass is mandatory for diagnosis, therapy and prognosis. For this reason our study is focused 
on this new perspective: study of epidemiology and surgical pathology of  primary cardiac tumors 
on this new population, because today diagnosis and treatment of surgically resected cardiac 
tumours have an important and expanding role. Was created a Registry of Veneto Region based on 
the population of patients subjected to surgical resection for primary  cardiac tumor. In Veneto 
Region, the total number of patients undergoing surgical resection for cardiac tumors within 12 
years was 279. According to the Census Data of Veneto Region, the median of resident population 
was 4.876.601 in the time interval 2005-2016. The annual average incidence in the general 
population of  Veneto Region is 0.47% (from 0,33% to 0,64%). This general data is similar to 
previus studies. Our results showes that 91,03% of primary cardiac tumors were benign and 8,9% 
malignant; such distribution corresponds to the results described in the literature (7-18). 
Approximately 85% of benign tumor were myxomas and 90% of malignant tumors were 
angiosarcomas and fibrosarcomas. In infants and children, the most dominant cardiac tumor was 
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rhabdomyoma, which is similar to the population we have observed. There is a peaked age 
distribution on population having the highest risk of  benign cardiac tumor formation between 60 
and 70 years old; malignant cardiac tumor having the highest risk at the age og 50-60.  Benign 
cardiac tumors do have a significant propensity for left sided cardiac structures with myxomas 
sharing their most common origin from left atrial structures (91%) and fibroelastomas having their 
most common origin at aortic valve leaflets (47,9%) and mitral valve leaflets ( 27,1%) (19-20). In 
opposition to, malignant cardiac tumors which have a propensity for the right side of the heart.  
In the second phase of our study  we have have analyzed the survival rate after the surgical 
resection.  Some of the earliest surgical series have reported patients who underwent cardiac 
myxoma resection as having an very-good long-term survival characteristics (21), our study 
document related to these patients showed no difference in terms of survival in the follow-up  (21-
23). Long-term survival of benign tumors was influenced by preoperative risk factors, ipertension 
and coronarary artery disease, that was a predictors of mortality. Regarding malignant primary 
cardiac, those are rare, but their survival after surgical resection was lower due to the infiltrating 
characteristics of the neoformation and the difficulties of the total resection. For this reason, we had 
one patient that had multiple recurrences and underwent a reoperation. Also one myxoma had a 
recurrence. Although, some authors insist on wide resection to prevent recurrence following 
incoplete resection (24)  and some others reports claim that simple tumor resection is sufficient 
because of the low recurrence rate (1,25), our recurred patients underwent total resection including 
reconstruction of interatrium defect and atrium side tumor pedicle. Probably the aggresive 
angiosarcoma in the first case and the multiple locations in the second case have determined 
reoperations like many reports describing (7, 24,25) patients with multiple recurrences occuring 
predominately in patients with myxoma.      
The clinical presentation of our population was different and dependends of primary cardiac tumors 
characteristics, similar to the literature series (4). The majority of patients presents dyspnea and 
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angina, and some patients have other symptoms such as lipothymia, arrhythmia  and barkin cough. 
Systemic embolism was about 8,9 % of patients and most of theme was cerebral embolism. 
Pulmonary embolism was rare and required emergency operation. About the 24,1 % of patients 
were asymptomatic.  
We identified preoperative, postoperative and follow-up NYHA class and we found improvement 
of the functional class. Preoperative NYHA functional classification has been implicated as a 
predictor of survival in many types of cardiac surgery (26). Although not surprising that also we 
also have an increasing of ejection fraction after tumors resection.  
Since the first successful resection of a cardiac tumor was a case of left atrial myxoma, as reported 
by Crafoord in 1954 (27), cardiac tumors resection gradually bacame a common operation with a 
very small risks and with a favorable prognosis (28).  We performed 68 patients with standard 
sternotomy and eleven patients with minimally-invasive approach, that become a conventional 
practice in other cardiac surgery procedures. Reber D et al have demonstrated that the left atrial 
myxoma resection via median sternotomy as a safe surgery with minimal mortality and minimal 
rate and recurrence (29) and it has been considered in our experience a routine approach. In some 
cases of small right side myxoma, small mitral valve and tricuspid valve fibroelastoma and one 
lipoma of interatrium septum we have performed an anterior minithoracotomy approach that is an 
exellent route for the right and left atrium.   We did not find significant differences beetween the 
two approach in terms of morbidity and mortality and recurrences. Similar results were noted by 
Pineda et al, when they evaluated 39 patients (22 with minimally invasive approach and 17 with 
median sternotomy) who had benign cardiac mass excision. They demonstrated that there were no 
significant differences in postoperative complications including mortality (30). The mass position 
must address surgical approach (31). Cardiac tumors arise mainly from the left atrium  septum (32) 
especially on our bigger myxoma population and this position was significant in term of survival 
also in the myxoma group. Three  surgical approaches can be applied: left atriotomy, right 
atriotomy and biatriotomy. Although the second and the third aprroach have been performed in 
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many hospital but the true surgical approach is still controversial. In the present study the first 
choise approach was the left atriotomy. Although some investigators (7,33) prefer the right 
atriotomy because they didn’t observe any recurrences (7,24,25). We consider the side access for 
almost all right cardiac masses. If the tumors was too big or its stalk was too sessile the complete 
resection biatriotomy was performed. Any attachment to the tumor was resected widely and 
sometimes we perfomed associated procedures such as atrial patch closure or right atrium patch 
reconstruction. Non myxoma cardiac tumors have arisen at various locations and for this reason, it 
is difficult to establish a regular surgcal strategy (7-16).  
Atrial arrhythmia occurred in 31,6 % of patients in our center and it was the most common 
complication, moreover four patients needed a permanent pacemaker, those results are similar to the  
one of the large Pineda’s  series (34).   
In conclusion, we have shown a consecutive series of cardiac tumors treated surgically in Veneto 
Region revealing the prevalence and pathological characteristics. Prognosis of rare cardiac primary 
tumors is favorable after surgical resection with a minimal morbidity and mortality. The location of 
the tumor is an important clinical indicator as to the histology of the various primary cardiac 
tumors. Clinical manifestations of cardiac tumors depend on the type of tumor, location, size, and 
friability, and can include symptoms related to the valvular or inflow-outflow tract obstruction, 
arrhythmias, thromboembolism, or constitutional symptoms.  
The strongest predictors of mortality are closely linked to the tumor histology, but also include 
preoperative clinical characteristics. Patients with myxoma has revealed the most most common 
cardiac tumors and there wasn’t significant difference between other benign tumors in terms of 
survival. Minimally-invasive approach should be considered an option for selected patiens.  The 
complete surgical resection of all of the tumors offers excellent long-term survival for the most 
patients and minimal recurrence rate.   
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